{"title": "Pfizer", "page_id": 62304, "revision_id": 1128232077, "revision_timestamp": "2022-12-19T03:21:18Z", "content": "{{Short description|American multinational pharmaceutical and biotechnology corporation}}\n{{About||the COVID-19 vaccine|Pfizer\u2013BioNTech COVID-19 vaccine|other uses}}\n{{Use American English|date=November 2015}}\n{{Use mdy dates|date= November 2015}}\n{{coord|40|45|01|N|73|58|21|W|display=title}}\n{{Infobox company\n| name = Pfizer Inc.\n| logo = Pfizer (2021).svg\n| logo_caption = \n| image = Pfizer World Headquarters Entrance.jpg\n| image_size = 250px\n| image_caption = Pfizer [[headquarters]] on [[42nd Street (Manhattan)|42nd Street]] in Midtown Manhattan\n| type = [[Public company|Public]]\n| traded_as = {{ubl|{{New York Stock Exchange|PFE}}|[[S&P 100]] component|[[S&P 500]] component|[[Russell 1000 Index]] component}}\n| founders = {{ubl|[[Charles Pfizer]]|[[Charles F. Erhart]]}}\n| founded = {{start date and age|1849}} in New York City\n| industry = {{Unbulleted list|[[Pharmaceutical industry|Pharmaceutical]]|[[Biotechnology]]}}\n| hq_location = 235 East 42nd Street\n| hq_location_city = New York City\n| hq_location_country = U.S.\n| area_served = Worldwide\n| key_people = [[Albert Bourla]] ([[CEO]])\n| products = {{hlist|[[Medication|Pharmaceutical drugs]]|[[vaccine]]s}}\n| revenue = {{increase}} [[US$|$]]81.29 billion<ref name=10K/>\n| revenue_year = 2021\n| operating_income = {{increase}} $22.46 billion<ref name=10K/>\n| income_year = 2021\n| net_income = {{increase}} $21.98 billion<ref name=10K/>\n| net_income_year = 2021\n| assets = {{increase}} $181.48 billion<ref name=10K/>\n| assets_year = 2021\n| equity = {{increase}} $77.46 billion<ref name=10K/>\n| equity_year = 2021\n| num_employees = approx. 79,000<ref name=10K/>\n| num_employees_year = 2021\n| website = {{url|pfizer.com}}\n| footnotes = <ref name=10K>{{cite web |url=https://s28.q4cdn.com/781576035/files/doc_financials/2021/ar/PFE-2021-Form-10K-FINAL.pdf |title=Pfizer Inc. 2021 Form 10-K Annual Report |publisher=Pfizer}}</ref>\n}}\n[[File:Shinjuku Bunka Quint Building.jpg|thumb|upright|The headquarters of Pfizer In Tokyo, Japan]]\n'''Pfizer Inc.''' ({{IPAc-en|\u02c8|f|a\u026a|z|\u0259r}} {{Respell|FY|z\u0259r}})<ref>{{Citation |last=Wells |first=John C. |title=Longman Pronunciation Dictionary |year=2008 |edition=3rd |publisher=[[Longman]] |isbn=9781405881180}}</ref> is an American [[Multinational corporation|multinational]] [[Pharmaceutical industry|pharmaceutical]] and [[biotechnology]] corporation headquartered on [[42nd Street (Manhattan)|42nd Street]] in [[Manhattan|Manhattan, New York City]]. The company was established in 1849 in New York by two German entrepreneurs, [[Charles Pfizer]] (1824\u20131906) and his cousin [[Charles F. Erhart]] (1821\u20131891).\n\nPfizer develops and produces [[medicine]]s and [[vaccine]]s for [[immunology]], [[oncology]], [[cardiology]], [[endocrinology]], and [[neurology]]. The company has several [[Medication#Blockbuster drug|blockbuster drug]]s or products that each generate more than {{US$|1}}{{nbsp}}billion in annual revenues.<ref name=10K/> In 2020, 52% of the company's revenues came from the United States, 6% came from each of China and Japan, and 36% came from other countries.<ref name=\"10K\"/>\n\nPfizer was a component of the [[Dow Jones Industrial Average]] [[stock market index]] from 2004 to August 2020.<ref>{{Cite news |url=https://www.usatoday.com/story/money/2020/08/25/exxon-pfizer-dow-jones-industrial-average-salesforce-djia/5630916002/ |last=Bomey |first=Nathan |title=Exxon Mobil, Pfizer removed from Dow Jones Industrial Average; Salesforce, Honeywell added |work=[[USA Today]] |date=August 25, 2020}}</ref><ref>{{Cite news |last=Stevens |first=Pippa |title=Salesforce, Amgen and Honeywell added to Dow in major shake-up to the average |url=https://www.cnbc.com/2020/08/24/salesforce-amgen-and-honeywell-added-to-dow-in-major-shakeup-to-the-average.html |work=[[CNBC]] |date=August 24, 2020}}</ref><ref>{{Cite news |url=https://www.bloomberg.com/news/articles/2020-08-24/dow-industrials-kicks-out-exxon-in-biggest-shakeup-since-2013 |title=Exxon Booted from Dow Industrials in Major Embrace of Tech |first1=Sarah |last1=Ponczek |first2=Katherine |last2=Greifeld |work=[[Bloomberg News]] |date=August 24, 2020 |url-access=limited}}\n</ref><ref>\n{{Cite news |url=https://www.barrons.com/articles/exxon-and-pfizer-just-got-booted-from-the-dow-jones-industrial-average-heres-whats-replacing-them-51598307204 |title=Exxon and Pfizer Just Got Booted From the Dow. Here's What's Replacing Them. |first=Ben |last=Levisohn |work=[[Barron's (newspaper)|Barron's]] |date=August 25, 2020 |url-access=limited}}\n</ref> The company ranks 64th on the [[Fortune 500]]<ref>{{cite web |title=Fortune 500: Pfizer |url=https://fortune.com/company/pfizer/fortune500/ |publisher=[[Fortune (magazine)|Fortune]]}}</ref> and 49th on the [[Forbes Global 2000]].<ref>{{cite web |title=Forbes Global 2000: Pfizer |url=https://www.forbes.com/companies/pfizer/?sh=67d299422d6b |work=[[Forbes]]}}</ref>\n\n==History==\n[[File:Charlespfizer.jpg|right|thumb|upright|Charles Pfizer (1824\u20131906)]]\n\n=== 1849\u20131950: Early history ===\nPfizer was founded in 1849 by [[Charles Pfizer]] and [[Charles F. Erhart]], two cousins who had immigrated to the United States from [[Ludwigsburg|Ludwigsburg, Germany]], the year before. The business produced chemical compounds, and was headquartered on Bartlett Street<ref name=\"Citycyclopedia\">Kenneth T. Jackson. ''The Encyclopedia of New York City''. The New York Historical Society; Yale University Press; September 1995. P. 895. {{ISBN|978-0-300-05536-8}}</ref> in [[Williamsburg, Brooklyn|Williamsburgh, New York]] where they produced an [[antiparasitic]] called [[santonin]]. This was an immediate success, although it was production of [[citric acid]] that led to Pfizer's growth in the 1880s. Pfizer continued to buy property in the area (by now the Williamsburg district of the city of [[Brooklyn, New York]] and beginning in 1898, the [[City of Greater New York]]) to expand its lab and factory, retaining offices on Flushing Avenue until the 1960s; the Brooklyn plant ultimately closed in 2009.<ref>{{Cite news |url=https://www.nytimes.com/2007/01/28/nyregion/28pfizer.html |title=Pfizer's Birthplace, Soon Without Pfizer |work=[[The New York Times]] |date=January 28, 2007}}</ref> Following their success with citric acid, Pfizer (at the now-demolished 295 Washington Avenue) and Erhart (at 280 Washington Avenue) established their main residences in the nearby [[Clinton Hill, Brooklyn|Clinton Hill]] district, known for its concentration of [[Gilded Age]] wealth. Pfizer spent summers in similarly exclusive [[Newport, Rhode Island]] where he died in 1906.{{citation needed|date=October 2022}}\n\nIn 1881, Pfizer moved its administrative headquarters to 81 Maiden Lane in [[Manhattan]], presaging the company's expansion to [[Chicago, Illinois|Chicago]] a year later.<ref name=\"Citycyclopedia\" /><ref name=collection/> By 1906 sales exceeded $3{{nbsp}}million.<ref name=history>{{Cite web |title=Company Timeline: a Legacy of Innovation |url=https://www.pfizer.com/about/history |url-status=live |website=Pfizer |archive-url=https://web.archive.org/web/20220408162711/https://www.pfizer.com/about/history |archive-date=2022-04-08 |access-date=2022-05-16}}</ref>\n\n[[World War I]] caused a shortage of [[calcium citrate]], which Pfizer imported from Italy for the manufacture of citric acid, and the company began a search for an alternative supply. Pfizer chemists learned of a fungus that ferments sugar to citric acid, and they were able to commercialize production of citric acid from this source in 1919. The company developed expertise in fermentation technology as a result. These skills were applied to the mass production of [[penicillin]], an [[antibiotic]], during [[World War II]] in response to the need to treat injured Allied soldiers.<ref name=Fermentation>{{Cite web |title=Penicillin Production through Deep-tank Fermentation \u2013 National Historic Chemical Landmark |url=https://www.acs.org/content/acs/en/education/whatischemistry/landmarks/penicillin.html |publisher=[[American Chemical Society]]}}</ref>\n\nOn June 2, 1942, the company incorporated in [[Delaware]].<ref name=10K/>\n\n=== 1950\u20131980: Pivot to pharmaceutical research and global expansion ===\nDue to price declines for [[penicillin]], Pfizer searched for new antibiotics with greater profit potential. Pfizer discovered [[oxytetracycline]] in 1950, and this changed the company from a manufacturer of [[fine chemical]]s to a research-based pharmaceutical company. Pfizer developed a [[drug discovery]] program focused on in vitro synthesis to augment its research in fermentation technology. In 1959, the company established an [[animal health]] division with a {{cvt|700|acre|km2|adj=on}} farm and research facility in [[Terre Haute, Indiana]].<ref name=Fermentation/>\n\nBy the 1950s, Pfizer had established offices in [[Belgium]], [[Brazil]], [[Canada]], [[Cuba]], [[Mexico]], [[Panama]], [[Puerto Rico]], and the [[United Kingdom]]. In 1960, the company moved its medical research laboratory operations out of [[New York City]] to a new facility in [[Groton, Connecticut]]. In 1980, Pfizer launched ''Feldene'' ([[piroxicam]]), a prescription anti-inflammatory medication that became Pfizer's first product to reach $1{{nbsp}}billion in revenue.<ref name=history/>\n\nIn 1965, John Powers, Jr. became [[chief executive officer]] of the company, succeeding John McKeen.<ref name=history/>\n\nAs the area surrounding its [[Brooklyn]] plant fell into decline in the 1970s and 1980s, the company formed a public-private partnership with New York City that encompassed the construction of low- and middle-income housing, the refurbishment of apartment buildings for the homeless and the establishment of a [[charter school]].<ref name=collection>{{Cite web |url=http://dlib.nyu.edu/findingaids/html/bhs/arc_084_pfizer/bioghist.html |title=Guide to the Pfizer Inc. collection ARC.084 |publisher=[[Brooklyn Public Library]]}}</ref>\n\nIn 1972, [[Edmund T. Pratt Jr.]] became [[chief executive officer]] of the company, succeeding John Powers, Jr.<ref name=history/>\n\n=== 1980\u20132000: Development of Viagra, Zoloft, and Lipitor ===\nIn 1981, the company received approval for ''Diflucan'' ([[fluconazole]]), the first oral treatment for severe [[fungal infection]]s including [[candidiasis]], [[blastomycosis]], [[coccidiodomycosis]], [[cryptococcosis]], [[histoplasmosis]], [[dermatophytosis]], and [[pityriasis versicolor]].<ref>{{cite web |title=Fluconazole |url=https://www.drugs.com/monograph/fluconazole.html |publisher=The American Society of Health-System Pharmacists |url-status=live |archive-url=https://web.archive.org/web/20161220231218/https://www.drugs.com/monograph/fluconazole.html |archive-date=20 December 2016}}</ref>\n\nIn 1986, Pfizer acquired the worldwide rights to ''Zithromax'' ([[azithromycin]]), a macrolide antibiotic that is recommended by the [[Infectious Disease Society of America]] as a first line treatment for certain cases of community-acquired pneumonia, from [[Pliva]].<ref name=\"best\">{{cite web |url=https://www.wipo.int/ipadvantage/en/details.jsp?id=906 |title=Azithromycin: A world best-selling Antibiotic |publisher=[[World Intellectual Property Organization]]}}</ref><ref>{{Cite journal |vauthors=Mandell LA, Wunderink RG, Anzueto A, etal |date=March 2007 |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |url=https://www.thoracic.org/statements/resources/mtpi/idsaats-cap.pdf |journal=Clin. Infect. Dis. |volume=44 Suppl 2 |issue=Suppl 2 |pages=S27\u201372 |doi=10.1086/511159 |pmc=7107997 |pmid=17278083}}</ref>\n\nIn 1989, Pfizer scientists Peter Dunn and Albert Wood created ''Viagra'' ([[sildenafil]]) for treating [[high blood pressure]] and [[angina]], a chest pain associated with [[coronary artery disease]]. In 1991, it was patented in the United Kingdom as a heart medication. Early trials for the medication showed that it did not work for the treatment of heart disease, but volunteers in the clinical trials had increased [[erection]]s several days after taking the drug. It was patented in the United States in 1996 and received approval by the [[Food and Drug Administration]] in March 1998. In December 1998, Pfizer hired [[Bob Dole]] as a spokesperson for the drug.<ref>{{Cite news |url=https://www.cnn.com/2013/03/27/health/viagra-anniversary-timeline/index.html |title=Viagra: The little blue pill that could |first=Jacque |last=Wilson |work=[[CNN]] |date=March 27, 2013}}</ref> The patents for Viagra expired in 2020.<ref>{{Cite news |url=https://www.theguardian.com/science/2019/jun/09/race-to-replace-viagra-patents-erectile-dysfunction-drug-medical-research-cialis-eroxon |title=The race to replace Viagra |first=David |last=Cox |work=[[The Guardian]] |date=June 9, 2019}}</ref>\n\nIn 1991, [[William C. Steere, Jr.]] became [[chief executive officer]] of the company, succeeding [[Edmund T. Pratt Jr.]]<ref>{{Cite news |url=https://www.latimes.com/archives/la-xpm-1991-03-29-fi-903-story.html |title=Pfizer Inc., New York, has elected its... |work=[[Los Angeles Times]] |date=March 29, 1991}}</ref>\n\nIn 1991 Pfizer also began marketing ''Zoloft'' ([[sertraline]]), an [[antidepressant]] of the [[selective serotonin reuptake inhibitor]] (SSRI) class developed nine years earlier by Pfizer chemists [[Kenneth Koe]] and Willard Welch. Sertraline is primarily prescribed for [[major depressive disorder]] in adult [[outpatients]] as well as [[obsessive-compulsive disorder]], [[panic disorder]], and [[social anxiety disorder]] in both adults and children. In 2005, the year before it became a generic drug, sales were over $3{{nbsp}}billion and over 100{{nbsp}}million people had been treated with the drug.<ref>{{Cite web |date=December 2015 |title=Kenneth Koe '45 |url=https://www.reed.edu/reed-magazine/in-memoriam/obituaries/_online_only/kenneth-koe-1945.html |url-status=live |access-date=2021-05-18 |website=Reed Magazine |publisher=[[Reed College]] |language=en-us |archive-url=https://web.archive.org/web/20220414055337/https://www.reed.edu/reed-magazine/in-memoriam/obituaries/_online_only/kenneth-koe-1945.html |archive-date=2022-04-14}}</ref> The patent for Zoloft expired in the summer of 2006.<ref>{{Cite news |last=Smith |first=Aaron |date=2006-04-04 |title=Who stands to gain when Zoloft goes generic? |work=[[CNN Money]] |url=https://money.cnn.com/2006/04/04/news/companies/antidepressants/ |access-date=2021-05-18}}</ref>\n\nIn 1996, [[Eisai (company)|Eisai]], in partnership with Pfizer, received [[Approved drug|approval]] from the [[Food and Drug Administration]] for [[donepezil]] under the brand Aricept for treatment of [[Alzheimer's disease]];<ref>{{Cite web |title=Highlights of Prescribing Information |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf |publisher=[[Food and Drug Administration]]}}</ref> Pfizer also received approval for ''Norvasc'' ([[amlodipine]]), an [[antihypertensive]] drug of the dihydropyridine calcium channel blocker class.<ref>{{Cite web |title=Drug Approval Package |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/19-787s007_Amlodipine.cfm |publisher=[[Food and Drug Administration]]}}</ref>\n\n[[File:Zoloft bottles.jpg|thumb|right|Bottles of ''Zoloft'' ([[sertraline]]), an [[antidepressant]]]]\nIn 1997, the company entered into a co-marketing agreement with [[Warner\u2013Lambert]] for ''Lipitor'' ([[atorvastatin]]), a [[statin]] for the treatment of [[hypercholesterolemia]]. Although atorvastatin was the fifth [[statin]] to be developed, clinical trials showed that atorvastatin caused a more dramatic reduction in [[low-density lipoprotein]] pattern C (LDL-C) than the other statin drugs. Upon its patent expiration in 2011, Lipitor was the best-selling drug ever, with approximately $125{{nbsp}}billion in sales over 14.5 years.<ref>{{Cite news |last=Mehta |first=Praful |date=2011-11-29 |title=Lipitor Patent Expiration - The End of an Era for Atorvastatin Sales |work=[[IHS Markit]] |url=https://ihsmarkit.com/research-analysis/lipitor-patent-expiration-atorvastatin-sales.html |access-date=2021-05-18}}</ref>\n\n=== 2000\u20132010: Further expansion ===\nIn 2001, [[Henry McKinnell]] became [[chief executive officer]] of the company, replacing [[William C. Steere, Jr.]]<ref name=\"longshot\">{{Cite news |url=https://www.nytimes.com/2006/07/29/business/29pfizer.html |title=A Long Shot Becomes Pfizer's Latest Chief Executive |first=Alex |last=Berenson |authorlink=Alex Berenson |work=[[The New York Times]] |date=July 29, 2006 |url-access=limited}}</ref>\n\nIn 2002, The [[Bill & Melinda Gates Foundation]] purchased stock in Pfizer.<ref>{{Cite news |last1=Bank |first1=David |last2=Buckman |first2=Rebecca |date=2002-05-17 |title=Gates Foundation Buys Stakes in Drug Makers |language=en-US |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/SB1021577629748680000 |access-date=2022-06-14 |issn=0099-9660}}</ref>\n\nIn 2004, the company received approval for ''Lyrica'' ([[pregabalin]]), an [[anticonvulsant]] and [[anxiolytic]] medication used to treat [[epilepsy]], [[neuropathic pain]], [[fibromyalgia]], [[restless leg syndrome]], and [[generalized anxiety disorder]].<ref>{{Cite web |title=Pregabalin |url=https://www.drugs.com/monograph/pregabalin.html |publisher=[[American Society of Health-System Pharmacists]]}}</ref><ref>{{cite journal |last1=Frampton |first1=James E. |title=Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder |journal=CNS Drugs |date=September 2014 |volume=28 |issue=9 |pages=835\u2013854 |doi=10.1007/s40263-014-0192-0 |pmid=25149863 |s2cid=5349255}}</ref><ref>{{cite journal |last1=Iftikhar |first1=I. H. |last2=Alghothani |first2=L. |last3=Trotti |first3=L. M. |title=Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis |journal=European Journal of Neurology |date=December 2017 |volume=24 |issue=12 |pages=1446\u20131456 |doi=10.1111/ene.13449 |pmid=28888061 |s2cid=22262972}}</ref> The United States patent on Lyrica was challenged by generic manufacturers and was upheld in 2014, extending the expiration date to 2018.<ref>{{Cite news |last=Decker |first=Susan |date=February 6, 2014 |title=Pfizer Wins Ruling to Block Generic Lyrica Until 2018 |work=[[Bloomberg News]] |url=https://www.bloomberg.com/news/2014-02-06/pfizer-wins-ruling-to-block-generic-lyrica-until-2018.html |url-access=subscription}}</ref> In 2016, the drug had sales of $4.2 billion.{{citation needed|date=April 2022}}\n\nIn July 2006, [[Jeff Kindler]] was named [[chief executive officer]] of the company, replacing [[Henry McKinnell]].<ref name=\"longshot\" /><ref>{{Cite news |date=July 28, 2006 |title=Pfizer names new CEO |work=[[CNN]] |url=https://money.cnn.com/2006/07/28/news/companies/pfizer_ceo/index.htm}}</ref>\n\nOn December 3, 2006, Pfizer ceased development of [[torcetrapib]], a drug that increases production of [[high density lipoprotein|HDL]], which reduces [[low density lipoprotein|LDL]] thought to be correlated to heart disease. During a [[Phase III clinical trial]] involving 15,000 patients, more deaths than expected occurred in the group that took the medicine, and the [[mortality rate]] of patients taking the combination of torcetrapib and Lipitor (82 deaths during the study) was 60% higher than those taking Lipitor alone (52 deaths during the study). Lipitor alone was not implicated in the results, but Pfizer lost nearly $1{{nbsp}}billion developing the failed drug and its stock price dropped 11% on the day of the announcement.<ref>{{Cite news |last1=Berenson |first1=Alex |last2=Pollack |first2=Andrew |date=December 5, 2006 |title=Pfizer Shares Plummet on Loss of a Promising Heart Drug |work=[[The New York Times]] |url=https://www.nytimes.com/2006/12/05/health/05pfizer.html |url-access=limited}}</ref><ref>{{Cite news |last=Berenson |first=Alex |date=December 3, 2006 |title=Pfizer Ends Studies on Drug for Heart Disease |work=[[The New York Times]] |url=https://www.nytimes.com/2006/12/03/health/03pfizer.html |url-access=limited |authorlink=Alex Berenson}}</ref><ref>{{Cite news |last=Agovino |first=Theresa |date=December 3, 2006 |title=Pfizer ends cholesterol drug development |publisher=[[The Seattle Times]] |agency=[[Associated Press]] |url=https://www.seattletimes.com/nation-world/cholesterol-drug-trials-are-halted/}}</ref><ref>{{cite journal |last1=Tanne |first1=Janice Hopkins |title=Pfizer stops clinical trials of heart drug |journal=BMJ |date=16 December 2006 |volume=333 |issue=7581 |pages=1237.2\u20131237 |doi=10.1136/bmj.39059.438044.DB |pmid=17170401 |pmc=1702474}}</ref>\n\nBetween 2007 and 2010, Pfizer spent $3.3{{nbsp}}million on investigations and legal fees and recovered about $5.1{{nbsp}}million, and had another $5{{nbsp}}million of pending recoveries from civil lawsuits against makers of [[counterfeit]] prescription drugs. Pfizer has hired customs and narcotics experts worldwide to track down fakes and assemble evidence that can be used to pursue civil suits for [[trademark infringement]].<ref>{{Cite news |last=Bennett |first=Simeon |date=July 8, 2010 |title=Pfizer: Civil Suits for Drug Counterfeiters |work=[[Bloomberg Businessweek]] |url=https://www.bloomberg.com/news/articles/2010-07-08/pfizer-civil-suits-for-drug-counterfeiters |url-access=limited}}</ref>\n\nIn July 2008, Pfizer announced 275 job cuts at its manufacturing facility in [[Kalamazoo, Michigan]]. Kalamazoo was previously the world headquarters of [[Upjohn Company]], which had been acquired as part of Pharmacia.<ref>{{Cite news |last=Jones |first=Al |date=July 15, 2008 |title=Pfizer job cuts don't equal a reduction in work load, says company spokesman |work=[[Booth Newspapers]] |url=https://www.mlive.com/kzgazette/2008/07/pfizer_job_cuts_dont_equal_a_r.html}}</ref><ref name=\":0\">{{Cite news |date=April 16, 2003 |title=It's official: Pfizer buys Pharmacia |work=[[CNN]] |url=https://money.cnn.com/2003/04/16/news/companies/pfizer_pharma/}}</ref>\n\n==== Acquisitions and mergers ====\nIn June 2000, Pfizer acquired Warner-Lambert outright for $116{{nbsp}}billion. To satisfy conditions imposed by antitrust regulators at the [[Federal Trade Commission]], Pfizer sold off or transferred stakes in several minor products, including RID (a shampoo for treatment of [[Head lice infestation|head lice]], sold to [[Bayer]]) and Warner-Lambert's antidepressant [[Celexa]] (which competes with Zoloft).<ref>{{Cite news |last=Hensley |first=Scott |date=June 20, 2000 |title=Pfizer Completes Stormy Takeover Of Warner-Lambert for $116 Billion |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/SB961456765639278103 |url-access=subscription}}</ref> The acquisition created what was, at the time, the second-largest pharmaceutical company worldwide.<ref>{{Cite news |last=Campbell |first=Todd |date=May 15, 2017 |title=Here are the 7 biggest mergers of all time |publisher=[[Business Insider]] |agency=[[The Motley Fool]] |url=https://www.businessinsider.com/here-are-the-7-biggest-mergers-of-all-time-2017-5#6-warner-lambert-warms-up-to-pfizer-89-billion-2}}</ref>\n\nIn 2003, Pfizer merged with [[Pharmacia]], and in the process acquired [[G.D. Searle, LLC|Searle]] and [[SUGEN]]. Searle had developed ''Flagyl'' ([[metronidazole]]), a [[nitroimidazole]] antibiotic medication used particularly for [[anaerobe|anaerobic]] [[bacterium|bacteria]] and [[protozoa]].<ref name=\":0\" /><ref>{{Cite web |title=Metronidazole Monograph for Professionals |url=https://www.drugs.com/monograph/metronidazole.html |publisher=[[Drugs.com]]}}</ref> Searle also developed [[celecoxib]] (''Celebrex'') a [[COX-2 inhibitor]] and [[nonsteroidal anti-inflammatory drug]] (NSAID) used to treat the [[pain]] and [[inflammation]] in [[osteoarthritis]], [[acute pain]] in adults, [[rheumatoid arthritis]], [[ankylosing spondylitis]], [[painful menstruation]], and [[juvenile rheumatoid arthritis]].<ref>{{cite web |date=11 November 2019 |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists}}</ref> [[SUGEN]], a company focused on [[protein kinase]] inhibitors, had pioneered the use of ATP-mimetic small molecules to block [[signal transduction]]. The [[SUGEN]] facility was shut down in 2003 by Pfizer, with the loss of more than 300 jobs, and several programs were transferred to Pfizer. These included [[sunitinib]] (''Sutent''), a cancer medication which was approved for human use by the FDA in January 2006.<ref>{{Cite news |url=https://www.bloomberg.com/news/articles/2005-11-20/the-spirit-of-a-startup-lives-on |title=The Spirit Of A Startup Lives On |work=[[Bloomberg Businessweek]] |date=November 21, 2005}}</ref><ref>{{Cite news |url=https://www.bizjournals.com/sanfrancisco/stories/2003/04/28/daily24.html |title=Pfizer expects to shutter South City biotech outpost |work=[[American City Business Journals]] |date=April 30, 2003}}</ref> A related compound, SU11654 ([[Toceranib]]), was also approved for [[cancer in dogs]], and the [[ALK inhibitor]] [[Crizotinib]] also grew out of a SUGEN program.<ref>{{Cite news |url=https://www.wsj.com/articles/SB10001424053111904009304576532892704206326 |title=FDA Approves Pfizer Lung-Cancer Drug |first=Jonathan D. |last=Rockoff |work=[[The Wall Street Journal]] |date=August 26, 2011 |url-access=subscription}}</ref><ref>{{cite book |doi=10.1016/B978-0-12-409547-2.12391-1 |chapter=Selective Kinase Inhibitors in Cancer |title=Comprehensive Medicinal Chemistry III |year=2017 |last1=Mortlock |first1=A.A. |last2=Wilson |first2=D.M. |last3=Kettle |first3=J.G. |last4=Goldberg |first4=F.W. |last5=Foote |first5=K.M. |pages=39\u201375 |isbn=978-0-12-803201-5}}</ref>\n\nIn October 2006, the company announced it would acquire PowerMed.<ref>{{Cite news |last=Barriaux |first=Marianne |date=October 9, 2006 |title=Pfizer buys vaccine developer PowderMed |work=[[The Guardian]] |url=https://www.theguardian.com/business/2006/oct/09/money5}}</ref>\n\nOn October 15, 2009, Pfizer acquired [[Wyeth]] for $68{{nbsp}}billion in cash and stock, including the assumption of debt, making Pfizer the largest pharmaceutical company in the world.<ref>{{Cite news |last1=Sorkin |first1=Andrew Ross |last2=Wilson |first2=Duff |date=January 25, 2009 |title=Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth |work=[[The New York Times]] |url=https://www.nytimes.com/2009/01/26/business/26drug.html |url-access=limited |issn=0362-4331 |authorlink1=Andrew Ross Sorkin |authorlink2=Duff Wilson}}</ref><ref>{{Cite news |date=October 15, 2009 |title=Pfizer completes $67 billion deal for rival Wyeth |work=[[Reuters]] |url=https://www.reuters.com/article/instant-article/idUSTRE59E4S320091015}}</ref><ref>{{cite news |last1=Karnitschnig |first1=Matthew |last2=Rockoff |first2=Jonathan D. |date=January 23, 2009 |title=Pfizer in Talks to Buy Wyeth |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/SB123268511212809429 |url-access=subscription}}</ref><ref name=\"worst\">{{Cite news |last=Edwards |first=Jim |date=January 23, 2009 |title=The Pfizer\u2013Wyeth Deal Worst-Case Scenario |work=[[CBS News]] |url=https://www.cbsnews.com/news/the-pfizer-wyeth-deal-worst-case-scenario/}}</ref><ref name=\"wyethpr\">{{Cite press release |title=PFIZER COMPLETES ACQUISITION OF WYETH |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_wyeth |publisher=Pfizer |date=October 14, 2009}}</ref> The acquisition of Wyeth provided Pfizer with a [[pneumococcal conjugate vaccine]], trademarked [[Pneumococcal conjugate vaccine#Prevnar|Prevnar 13]]; this is used for the prevention of invasive pneumococcal infections. The introduction of the original, 7-valent version of the vaccine, developed by [[Wyeth]] in February 2000, led to a 75% reduction in the incidence of invasive pneumococcal infections among children under age{{nbsp}}5 in the United States. Pfizer introduced an improved version of the vaccine in 2010, for which it was granted a patent in India in 2017. Prevnar 13 provides coverage of 13 bacterial variants, expanding beyond the original 7-valent version.<ref name=\"wyethpr\" /> By 2012, the rate of invasive infections among children under age{{nbs}}5 had been reduced by an additional 50%.<ref name=\"cdc.gov\">{{Cite web |date=April 5, 2019 |title=CDC \u2013 ABCs: Surveillance Reports main page \u2013 Active Bacterial Core surveillance |url=https://www.cdc.gov/abcs/reports-findings/surv-reports.html}}</ref><ref>{{Cite web |last=Herper |first=Matthew |date=August 24, 2020 |title=In the race for a Covid-19 vaccine, Pfizer turns to a scientist with a history of defying skeptics \u2013 and getting results |url=https://www.statnews.com/2020/08/24/pfizer-edge-in-the-race-for-a-covid-19-vaccine-could-be-a-scientist-with-two-best-sellers-to-her-credit/ |website=[[Stat (website)|Stat]]}}</ref>\n\n=== 2010\u20132020: Further discoveries and acquisitions ===\nIn 2010, [[Ian Read]] was named [[chief executive officer]] of the company.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20190927005072/en/Ian-Read-to-Retire-as-Executive-Chairman-of-Pfizer%E2%80%99s-Board-of-Directors-Chief-Executive-Officer-Dr.-Albert-Bourla-Named-Chairman |title=Ian Read to Retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman |publisher=[[Business Wire]] |date=September 27, 2019}}</ref>\n\nIn February 2011, Pfizer announced the closure of its UK research and development facility (formerly also a manufacturing plant) in [[Sandwich, Kent]], which at the time employed 2,400 people.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-12335801 |title=Pfizer to close UK research site |work=[[BBC News]] |date=February 1, 2011}}</ref> In March 2011, Pfizer acquired [[King Pharmaceuticals]] for $3.6{{nbsp}}billion in cash. King produced emergency injectables such as the [[EpiPen]].<ref>{{Cite news |url=https://www.modernhealthcare.com/article/20110301/NEWS/303019922/pfizer-closes-king-pharmaceuticals-acquisition |title=Pfizer closes King Pharmaceuticals acquisition |first=Maureen |last=Mckinney |work=[[Modern Healthcare]] |date=March 1, 2011}}</ref>\n\nOn September 4, 2012, the FDA approved [[bosutinib]] (''Bosulif'') for [[chronic myelogenous leukemia]] (CML), a rare type of [[leukemia]] and a blood and [[bone marrow]] disease that affects primarily older adults.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-leukemia/fda-approves-pfizer-leukemia-drug-idUSBRE88314720120904 |title=FDA approves Pfizer leukemia drug |first=Anna |last=Yukhananov |work=[[Reuters]] |date=September 4, 2012}}</ref> In November 2012, Pfizer received approval from the [[Food and Drug Administration]] for Xeljanz, a [[tofacitinib]], for [[rheumatoid arthritis]] and [[ulcerative colitis]].<ref>{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214orig1s000toc.cfm |title=Drug Approval Package |publisher=[[Food and Drug Administration]]}}</ref> The drug had sales of $1.77{{nbsp}}billion in 2018, and in January 2019, it was the top drug in the United States for [[direct-to-consumer advertising]], passing [[adalimumab]] (''Humira'').<ref>{{Cite news |title=Pfizer switches RA patients to lower dose of fast-growing Xeljanz as safety issues arise in postmarketing study |url=https://www.fiercepharma.com/pharma/postmarketing-study-pfizer-switches-ra-patients-to-lower-xeljanz-dose-safety-concerns |website=[[FiercePharma]] |first=Eric |last=Sagonowsky |date=February 20, 2019}}</ref>\n\nOn February 1, 2013, [[Zoetis]], the Agriculture Division of Pfizer and later Pfizer Animal Health, became a [[public company]] via an [[initial public offering]], raising $2.2{{nbsp}}billion.<ref>{{Cite press release |title=Zoetis\u2122 Files IPO Registration Statement |url=https://www.zoetisus.com/news-and-media/zoetis-files-ipo-registration-statement.aspx |publisher=[[Business Wire]] |date=August 13, 2012}}</ref><ref>{{Cite news |url=https://dealbook.nytimes.com/2013/02/01/shares-of-zoetis-surge-on-debut/ |last=J. de la Merced |first=Michael |title=Shares of Zoetis Surge on Debut |work=[[The New York Times]] |date=February 1, 2013 |url-access=limited}}</ref><ref>{{Cite news |title=Zoetis Raises $2.2 Billion in IPO |url=https://www.wsj.com/articles/SB10001424127887323701904578276530830057770 |last=Dieterich |first=Chris |work=[[The Wall Street Journal]] |date=January 31, 2013 |url-access=subscription}}</ref><ref>{{Cite news |url=https://www.cbsnews.com/news/shares-of-animal-health-company-zoetis-soar-in-ipo/ |title=Shares of animal health company Zoetis soar in IPO |agency=[[Associated Press]] |publisher=[[CBS News]] |date=February 1, 2013}}</ref> Later in 2013, Pfizer completed the [[corporate spin-off]] of its remaining stake in [[Zoetis]].<ref>{{Cite news |url=https://www.wsj.com/articles/SB10001424127887323975004578498994013821124 |title=Pfizer to Spin Off Remaining Zoetis Stake |first=Peter |last=Loftus |work=[[The Wall Street Journal]] |date=May 22, 2013}}</ref><ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-zoetis/pfizer-to-spin-off-zoetis-stake-to-shareholders-idUSBRE94L0JB20130522 |title=Pfizer to spin off Zoetis stake to shareholders |first1=Caroline |last1=Humer |first2=Ransdell |last2=Pierson |work=[[Reuters]] |date=May 22, 2013}}</ref>\n\nIn September 2014, the company acquired Innopharma for $225{{nbsp}}million, plus up to $135{{nbsp}}million in milestone payments, in a deal that expanded Pfizer's range of generic and injectable drugs.<ref>{{Cite news |url=https://www.fiercepharma.com/pharma/pfizer-completes-acquisition-of-innopharma |title=Pfizer Completes Acquisition Of InnoPharma |first=Emily |last=Wasserman |work=[[FiercePharma]] |date=September 29, 2014}}</ref><ref>{{Cite news |title=Pfizer to Acquire InnoPharma for Up to $360M |url=https://www.genengnews.com/news/pfizer-to-acquire-innopharma-for-up-to-360m/ |website=[[genengnews.com]] |date=July 16, 2014}}</ref>\n\nOn January 5, 2015, the company announced it would acquire a controlling interest in Redvax, expanding its vaccine portfolio targeting human [[cytomegalovirus]].<ref>{{Cite news |title=Pfizer Buys Redvax, Boosting Vaccine Portfolio |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-redvax-boosting-vaccine-portfolio/ |website=[[genengnews.com]] |date=January 5, 2015}}</ref> In February 2015, the company received approval from the [[Food and Drug Administration]] for [[palbociclib]] (''Ibrance'') for treatment of certain types of [[breast cancer]].<ref>{{cite journal |last1=Beaver |first1=Julia A. |last2=Amiri-Kordestani |first2=Laleh |last3=Charlab |first3=Rosane |last4=Chen |first4=Wei |last5=Palmby |first5=Todd |last6=Tilley |first6=Amy |last7=Zirkelbach |first7=Jeanne Fourie |last8=Yu |first8=Jingyu |last9=Liu |first9=Qi |last10=Zhao |first10=Liang |last11=Crich |first11=Joyce |last12=Chen |first12=Xiao Hong |last13=Hughes |first13=Minerva |last14=Bloomquist |first14=Erik |last15=Tang |first15=Shenghui |last16=Sridhara |first16=Rajeshwari |last17=Kluetz |first17=Paul G. |last18=Kim |first18=Geoffrey |last19=Ibrahim |first19=Amna |last20=Pazdur |first20=Richard |last21=Cortazar |first21=Patricia |title=FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor\u2013Positive, HER2-Negative Metastatic Breast Cancer |journal=Clinical Cancer Research |date=1 November 2015 |volume=21 |issue=21 |pages=4760\u20134766 |doi=10.1158/1078-0432.CCR-15-1185 |pmid=26324739 |s2cid=24762535 |doi-access=free}}</ref><ref>{{Cite web |url=https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance |title=Palbociclib (IBRANCE) |date=February 9, 2019 |publisher=[[Food and Drug Administration]]}}</ref> In March 2015, the company announced it would restart its collaboration with [[Eli Lilly and Company]] surrounding the [[Phase III trial]] of [[Tanezumab]].<ref>{{Cite news |title=Pfizer, Lilly to Resume Phase III Tanezumab Clinical Program |url=https://www.genengnews.com/topics/drug-discovery/pfizer-lilly-to-resume-phase-iii-tanezumab-clinical-program/ |website=[[genengnews.com]] |date=March 23, 2015}}</ref> In May 2015, Pfizer and a [[Bar-Ilan University]] laboratory announced a partnership based on the development of medical [[DNA nanotechnology]].<ref>{{Cite news |last=Gali |first=Weinreb |title=Pfizer to collaborate on Bar-Ilan DNA robots |work=[[Globes (newspaper)|Globes]] |url=https://en.globes.co.il/en/article-pfizer-to-collaborate-on-bar-ilan-dna-robots-1001036703 |date=May 14, 2015}}</ref> In June 2015, the company acquired ''Nimenrix'' and ''Mencevax'', [[meningococcal vaccine]]s, from GlaxoSmithKline for around $130{{nbsp}}million.<ref>{{Cite news |title=Pfizer Buys Two GSK Meningitis Vaccines for $130M |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/ |website=[[genengnews.com]] |date=June 22, 2015}}</ref> In September 2015, Pfizer acquired [[Hospira]] for $17{{nbsp}}billion, including the assumption of debt.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20150903005752/en/Pfizer-Completes-Acquisition-of-Hospira |title=Pfizer Completes Acquisition of Hospira |publisher=Pfizer |via=[[Business Wire]] |date=September 3, 2015}}</ref><ref>{{Cite news |url=https://www.thepharmaletter.com/article/pfizer-completes-17-billion-hospira-acquisition |title=Pfizer completes $17-billion Hospira acquisition |work=[[The Pharma Letter]] |date=September 4, 2015}}</ref><ref>{{Cite news |first1=David |last1=Gelles |first2=Katie |last2=Thomas |title=Pfizer Bets $15 Billion on New Class of Generic Drugs |url=https://dealbook.nytimes.com/2015/02/05/pfizer-to-buy-hospira-a-drug-maker-for-15-2-billion-in-cash |work=[[The New York Times]] |date=February 5, 2015 |url-access=limited}}</ref><ref>{{Cite web |title=8-K |url=https://www.sec.gov/Archives/edgar/data/78003/000119312515037588/d866443d8k.htm |publisher=[[U.S. Securities and Exchange Commission]] |date=February 6, 2015}}</ref><ref>{{Cite press release |title=Pfizer to Acquire Hospira |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_hospira |work=Pfizer}}</ref><ref>{{Cite news |last=Neilan |first=Catherine |title=Pfizer, Hospira share prices to soar after $17bn deal announced |url=https://www.cityam.com/pfizer-hospira-share-prices-soar-after-17bn-deal-announced/ |work=[[City A.M.]] |date=February 5, 2015}}</ref> [[Hospira]] was the largest producer of generic injectable pharmaceuticals in the world.<ref>{{Cite news |title=US-based Hospira to buy Orchid Chemicals' injectables biz for $400 mn |url=https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/us-based-hospira-to-buy-orchid-chemicals-injectables-biz-for-400-mn/articleshow/5342003.cms |first1=Mohit |last1=Bhalla |first2=Khomba |last2=Singh |work=[[The Economic Times]] |date=December 16, 2009}}</ref> On November 23, 2015, Pfizer and [[Allergan]] announced a planned $160{{nbsp}}billion merger, in the largest pharmaceutical deal ever and the third largest corporate merger in history. The proposed transaction contemplated that the merged company maintain Allergan's [[Republic of Ireland]] domicile, resulting in the new company being subject to [[corporation tax]] at the relatively low rate of 12.5%.<ref>{{Cite news |title=Pfizer seals $160bn Allergan deal to create drugs giant |url=https://www.bbc.co.uk/news/business-34900344 |work=[[BBC News]] |date=November 23, 2015}}</ref> The deal was to constitute a [[reverse merger]], whereby Allergan acquired Pfizer, with the new company then changing its name to \"Pfizer, plc\".<ref>{{Cite news |title=Pfizer to buy Allergan in $160 billion deal |url=https://www.reuters.com/article/us-allergan-m-a-pfizer/pfizer-to-buy-allergan-in-160-billion-deal-idUSKBN0TB0UT20151124 |first1=Ransdell |last1=Pierson |first2=Bill |last2=Berkrot |work=[[Reuters]] |date=November 24, 2015}}</ref><ref>{{Cite news |title=Pfizer to Acquire Allergan for $160B |url=https://www.genengnews.com/news/pfizer-to-acquire-allergan-for-160b/ |work=[[genengnews.com]] |date=November 23, 2015}}</ref><ref>{{Cite news |first=Cynthia |last=Koons |title=Pfizer and Allergan to Combine With Joint Value of $160 Billion |url=https://www.bloomberg.com/news/articles/2015-11-22/pfizer-allergan-said-to-be-close-to-150-billion-merger |work=[[Bloomberg News]] |date=November 22, 2015 |url-access=limited}}</ref> On April 6, 2016, Pfizer and Allergan terminated the merger agreement after the [[Obama administration]] and the [[United States Department of the Treasury]] introduced new laws intended to limit [[corporate inversion]]s (the extent to which companies could move their headquarters overseas in order to reduce the amount of taxes they pay).<ref>{{Cite news |last=Bray |first=Chad |title=Pfizer and Allergan Call Off Merger After Tax-Rule Changes |url=https://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html |work=[[The New York Times]] |date=April 6, 2016 |url-access=limited}}</ref><ref>{{Cite news |last1=Humer |first1=Caroline |last2=Banerjee |first2=Ankur |title=Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change |work=[[Reuters]] |url=https://www.reuters.com/article/us-allergan-m-a-pfizer-idUSKCN0X3188 |date=April 6, 2016}}</ref>\n\nIn June 2016, the company acquired Anacor Pharmaceuticals for $5.2{{nbsp}}billion, expanding its portfolio in both inflammation and immunology drugs areas.<ref>{{cite press release |url=https://www.businesswire.com/news/home/20160624005299/en/Pfizer-Completes-Acquisition-of-Anacor |title=Pfizer Completes Acquisition of Anacor |publisher=Pfizer |via=[[Business Wire]] |date=June 24, 2016}}</ref><ref>{{Cite news |title=Pfizer to Acquire Anacor Pharmaceuticals for $5.2B |url=https://www.genengnews.com/news/pfizer-to-acquire-anacor-pharmaceuticals-for-5-2b/ |website=[[genengnews.com]] |date=May 16, 2016}}</ref> In August 2016, the company made a $40{{nbsp}}million bid for the assets of BIND Therapeutics, which was in [[bankruptcy]].<ref>{{Cite news |title=Pfizer Places High Bid of $40M for BIND Therapeutics |url=https://www.genengnews.com/news/pfizer-places-high-bid-of-40m-for-bind-therapeutics/ |website=[[genengnews.com]] |date=July 27, 2016}}</ref> The same month, the company acquired Bamboo Therapeutics for $645{{nbsp}}million, expanding its gene therapy offerings.<ref>{{Cite news |title=Pfizer Acquires Bamboo Therapeutics in a $645M Deal |url=https://www.genengnews.com/news/pfizer-acquires-bamboo-therapeutics-in-a-645m-deal/ |website=[[genengnews.com]] |date=August 1, 2016}}</ref> In September 2016, the company acquired cancer drug-maker [[Medivation]] for $14{{nbsp}}billion.<ref>{{Cite news |title=Pfizer to Acquire Medivation for $14B |url=https://www.genengnews.com/news/pfizer-to-acquire-medivation-for-14b/ |website=[[genengnews.com]] |date=August 22, 2016}}</ref><ref>{{Cite news |title=Pfizer to buy cancer drug firm Medivation for $14bn |work=[[BBC News]] |url=https://www.bbc.co.uk/news/business-37150531 |date=August 22, 2016}}</ref><ref>{{Cite press release |url=https://www.businesswire.com/news/home/20160928005824/en/ |title=Pfizer Completes Acquisition of Medivation |publisher=OncoImmune |via=[[Business Wire]] |date=September 28, 2016}}</ref> In October 2016, the company licensed the anti-[[CTLA4]] monoclonal antibody, ONC-392, from OncoImmune.<ref>{{Cite news |url=https://www.genengnews.com/topics/drug-discovery/oncoimmune-licenses-onc-392-to-pfizer-for-up-to-250m/ |title=OncoImmune Licenses ONC-392 to Pfizer for Up to $250M |work=[[genengnews.com]] |date=October 15, 2016}}</ref><ref>{{cite press release |url=https://www.businesswire.com/news/home/20160915005151/en/OncoImmune-Announces-Option-and-License-Agreement-with-Pfizer-Inc. |title=OncoImmune Announces Option and License Agreement with Pfizer Inc. |publisher=Pfizer |via=[[Business Wire]] |date=September 15, 2016}}</ref> In November 2016, Pfizer funded a $3,435,600 study with the [[CDC Foundation]] to research \"screen-and-treat\" strategies for [[cryptococcal disease]] in [[Botswana]].<ref name=\":4\">{{Cite web |date=2021-12-09 |title=CDC Foundation Active Programs October 1, 2020 \u2013 September 30, 2021 |url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |url-status=live |archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |archive-date=2022-01-15 |access-date=2022-08-06 |website=[[CDC Foundation]]}}</ref> In December 2016, Pfizer acquired [[AstraZeneca]]'s small-molecule antibiotics business for $1.575 billion.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20161222005395/en/Pfizer-Completes-Acquisition-of-Small-Molecule-Anti-Infective-Business-From-AstraZeneca |title=Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca |publisher=Pfizer |via=[[Business Wire]] |date=December 23, 2016}}</ref><ref>{{Cite news |title=Pfizer Buys AstraZeneca Antibiotics for Up to $1.575B |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-astrazeneca-antibiotics-for-up-to-1-575b/ |website=[[genengnews.com]] |date=August 24, 2016}}</ref><ref>{{Cite news |title=Pfizer grabs AZ antibiotics in $1.5B deal. Pre-split prep or just another sales-boosting buy? |url=https://www.fiercepharma.com/pharma/pfizer-grabs-az-antibiotics-1-5b-deal-pre-split-prep-or-just-another-sales-boosting-buy |first=Tracy |last=Staton |work=[[FiercePharma]] |date=August 24, 2016}}</ref>\n\nIn January 2018, Pfizer announced that it would end its work on research into treatments for [[Alzheimer's disease]] and [[Parkinsonism]] (a symptom of [[Parkinson's disease]] and other conditions). The company said about 300 researchers would lose their jobs.<ref>{{Cite news |last=Hiltzik |first=Michael | author-link=Michael Hiltzik |title=Pfizer, pocketing a big tax cut from Trump, will end investment in Alzheimer's and Parkinson's research |url=https://www.latimes.com/business/hiltzik/la-fi-hiltzik-pfizer-20180108-story.html |work=[[Los Angeles Times]] |date=January 8, 2018 |url-access=subscription}}</ref> In July 2018, the [[Food and Drug Administration]] approved [[enzalutamide]], developed by Pfizer and [[Astellas Pharma]] for patients with [[castration]]-resistant [[prostate cancer]].<ref>{{Cite press release |url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-castration-resistant-prostate-cancer |title=FDA approves enzalutamide for castration-resistant prostate cancer |publisher=[[Food and Drug Administration]] |date=July 13, 2018}}</ref> In August 2018, Pfizer signed an agreement with [[BioNTech]] to conduct joint research and development activities regarding [[mRNA]]-based [[influenza vaccine]]s.<ref>{{Cite press release |title=BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza |url=https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-signs-collaboration-agreement-pfizer-develop-mrna-based |publisher=[[BioNTech]] |date=August 16, 2018}}</ref> In October 2018, effective January 1, 2019, [[Albert Bourla]] was promoted to [[chief executive officer]], succeeding [[Ian Read]], his mentor.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-ceo/pfizer-to-replace-longtime-ceo-read-with-veteran-bourla-idUSKCN1MB29D |title=Pfizer to replace longtime CEO Read with veteran Bourla |first1=Tamara |last1=Mathias |first2=Ankur |last2=Banerjee |date=October 1, 2018 |work=[[Reuters]]}}</ref><ref>{{cite news |last=Maidenberg |first=Micah |title=Pfizer Prepares for CEO Transition With Executive Suite Changes |url=https://www.wsj.com/articles/pfizer-prepares-for-ceo-transition-with-executive-suite-changes-1539095075 |work=[[The Wall Street Journal]] |date=October 9, 2018 |url-access=subscription}}</ref><ref>{{cite news |url=https://www.businessinsider.com/who-is-albert-bourla-next-pfizer-ceo-2018-10 |title=Pfizer's CEO is stepping down after 8 years \u2014 meet the man who will be replacing him |last=Ramsey |first=Lydia |work=[[Business Insider]] |date=October 1, 2018 |url-access=subscription}}</ref><ref>{{cite news |last=Jarvis |first=Lisa M. |title=Pfizer unveils CEO succession plan |work=[[Chemical & Engineering News]] |url=https://cen.acs.org/pharmaceuticals/Pfizer-unveils-CEO-succession-plan/96/i40 |date=October 3, 2018}}</ref>\n\nIn July 2019, the company acquired Therachon for up to $810{{nbsp}}million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as [[achondroplasia]].<ref>{{Cite news |url=https://www.spglobal.com/marketintelligence/en/news-insights/trending/sWCcSrMgL8UmeCJXuuGp-w2 |title=Pfizer completes acquisition of Therachon to bolster rare disease drug portfolio |first=Ravikash |last=Bakolia |work=[[S&P Global]] |date=July 1, 2019}}</ref> Also in July, Pfizer acquired [[Array Biopharma]] for $10.6{{nbsp}}billion, boosting its oncology pipeline.<ref>{{Cite press release |url=https://www.businesswire.com/news/home/20190730005590/en/Pfizer-Completes-Acquisition-of-Array-Biopharma |title=Pfizer Completes Acquisition of Array Biopharma |publisher=Pfizer |via=[[Business Wire]] |date=July 30, 2019}}</ref> In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a [[joint venture]] owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a [[public company]]. The transaction built on a 2018 transaction where GlaxoSmithKline acquired [[Novartis]]' stake in the GSK-Novartis consumer healthcare joint business.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-46616713 |title=GlaxoSmithKline and Pfizer merge healthcare arms |work=[[BBC News]] |date=December 19, 2018}}</ref> The transaction followed negotiations with other companies including [[Reckitt Benckiser]],<ref>{{Cite news |title=Reckitt Benckiser's still keen on a Pfizer OTC buy. But can it afford one? |url=https://www.fiercepharma.com/pharma/reckitt-benckiser-s-still-keen-a-pfizer-otc-buy-but-can-it-afford-one |website=[[FiercePharma]] |first=Carly |last=Helfand |date=October 16, 2017}}</ref> [[Sanofi]], [[Johnson & Johnson]],<ref>{{Cite news |title=Sanofi, J&J could join GlaxoSmithKline, Reckitt in $20B bidding war for Pfizer OTC: report |url=https://www.fiercepharma.com/pharma/sanofi-j-j-could-join-gsk-reckitt-20b-bidding-war-for-pfizer-otc-report |website=[[FiercePharma]] |first=Carly |last=Helfand |date=October 26, 2017}}</ref> and [[Procter & Gamble]].<ref>{{Cite news |title=GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend? |url=https://www.fiercepharma.com/pharma/glaxosmithkline-s-eyeing-pfizer-s-otc-unit-but-will-a-buy-imperil-its-dividend |website=[[FiercePharma]] |first=Carly |last=Helfand |date=October 25, 2017}}</ref> In September 2019, Pfizer initiated a study with the [[CDC Foundation]] to investigate the tracking of [[healthcare-associated infection]]s, scheduled to run through to June 2023.<ref name=\":4\" /> In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its [[cryptococcal disease]] screening and treatment research in nine African countries.<ref name=\":4\" />\n\nIn September 2020, the company acquired a 9.9% stake in [[CStone Pharmaceuticals]] for $200{{nbsp}}million (HK$1.55{{nbsp}}billion), helping to commercialise its anti-[[PD-L1]] monoclonal antibody, CS1001.<ref>{{Cite news |title=Pfizer to buy 9.9% of CStone for $200 million, eyes collaboration |url=https://www.reuters.com/article/us-cstone-pfizer/pfizer-to-buy-9-9-of-cstone-for-200-million-eyes-collaboration-idUKKBN26L01D |work=[[Reuters]] |date=September 29, 2020}}</ref> In October 2020, the company acquired Arixa Pharmaceuticals.<ref>{{Cite news |url=https://www.fiercebiotech.com/biotech/pfizer-snaps-up-antibiotics-maker-arixa-and-its-oral-avycaz-follow-up |title=Biotech Pfizer snaps up antibiotics maker Arixa and its oral Avycaz follow-up |first=Amirah |last=Al Idrus |work=[[FiercePharma]] |date=October 22, 2020}}</ref> In November 2020, using a [[Reverse Morris Trust]] structure, Pfizer merged its off-patent branded and [[generic drug]] business, known as Upjohn, with [[Mylan]] to form [[Viatris]], owned 57% by Pfizer shareholders.<ref>{{Cite news |url=https://www.nasdaq.com/articles/pfizer-completes-combination-of-upjohn-and-mylan-viatris-to-begin-trading-on-nov.-17-2020 |title=Pfizer Completes Combination Of Upjohn And Mylan; Viatris To Begin Trading On Nov. 17 |work=[[Nasdaq]] |date=November 16, 2020}}</ref><ref>{{Cite news |url=https://www.post-gazette.com/business/healthcare-business/2020/11/16/Mylan-merger-Upjohn-Viatris-bresch-coury-Pfizer-cost-cuts-generic-drugs/stories/202011160111 |title=Mylan completes merger with Upjohn to form Viatris |first=Patricia |last=Sabatini |work=[[Pittsburgh Post-Gazette]] |date=November 16, 2020}}</ref>\n\n=== 2021\u2013onwards: Corporate developments and acquisitions ===\nOn January 5, 2021, Pfizer introduced a new [[logo]].<ref>{{Cite news |last=Bruell |first=Alexandra |title=Pfizer Introduces New Logo Playing Up Role in Drug Creation |url=https://www.wsj.com/articles/pfizer-introduces-new-logo-playing-up-role-in-drug-creation-11609844400 |work=[[The Wall Street Journal]] |date=January 5, 2021 |issn=0099-9660 |url-access=subscription}}</ref> In April 2021, Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal compound [[fosmanogepix]] (APX001).<ref>{{cite news |url=https://www.fiercebiotech.com/biotech/pfizer-buys-amplyx-to-grow-infectious-disease-pipeline |title=Pfizer buys Amplyx to grow infectious disease pipeline |first=Nick Paul |last=Taylor |work=[[FiercePharma]] |date=April 28, 2021}}</ref><ref>{{Cite news |url=https://www.sandiegouniontribune.com/business/biotech/story/2021-04-28/pfizer-acquires-fungus-fighting-san-diego-biotech-amplyx |title=Pfizer acquires fungus-fighting San Diego biotech |first=Jonathan |last=Wosen |work=[[The San Diego Union-Tribune]] |date=April 28, 2021}}</ref> In August, the company announced it would acquire Trillium Therapeutics Inc and its immuno-oncology portfolio for $2.3 billion ($18.50 per share).<ref>{{Cite news |url=https://www.reuters.com/business/pfizer-buy-trillium-therapeutics-226-bln-deal-2021-08-23/ |title=Pfizer to buy cancer drug developer Trillium in $2.3 BLN deal |newspaper=Reuters |date=August 23, 2021}}</ref><ref>{{Cite web |url=https://www.biospace.com/article/releases/pfizer-to-acquire-trillium-therapeutics-inc-/?s=79 |title=Pfizer to Acquire Trillium Therapeutics Inc}}</ref> In December, Pfizer announced that it had agreed to acquire [[Arena Pharmaceuticals]] for $6.7 billion in cash.<ref>{{cite web |title=Pfizer bets on Arena's promising bowel disease treatment in $6.7 bln deal |url=https://www.reuters.com/markets/deals/pfizer-acquire-arena-pharmaceuticals-67-bln-deal-2021-12-13 |work=[[Reuters]] |date=December 13, 2021 |access-date=December 13, 2021}}</ref><ref>{{cite web |title=Pfizer to Acquire Arena Pharmaceuticals in $6.7 Billion Deal |url=https://www.wsj.com/articles/pfizer-to-acquire-arena-pharmaceuticals-in-6-7-billion-deal-11639414813 |work=[[Wall Street Journal]] |last=Walker |first=Joseph |date=December 13, 2021 |access-date=December 13, 2021}}</ref> In March 2022, it was announced the acquisition of Arena Pharmaceuticals had been concluded.<ref>{{Cite web |date=2022-03-14 |title=Pfizer concludes Arena Pharmaceuticals acquisition for $6.7bn |url=https://www.pharmaceutical-technology.com/news/pfizer-arena-pharmaceuticals-acquisition/ |access-date=2022-03-14 |website=Pharmaceutical Technology |language=en-US}}</ref> In April 2022, the company announced it would acquire ReViral Ltd, for up to $525 million, gaining access to experimental drugs used to combat [[respiratory syncytial virus]] infections. Pfizer completed the acquisition of ReViral in June 2022.<ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-rsv-drug-developer-reviral-up-525-mln-2022-04-07/ | title=Pfizer boosts respiratory drug portfolio with ReViral purchase | newspaper=Reuters | date=April 7, 2022 | last1=Satija | first1=Bhanvi }}</ref><ref>{{Cite web |date=2022-06-10 |title=Pfizer acquires biopharma firm ReViral for up to $525m |url=https://www.pharmaceutical-technology.com/news/pfizer-acquires-biopharma-reviral/ |access-date=2022-06-10 |website=Pharmaceutical Technology |language=en-US}}</ref>\n\nIn October 2022, the company completed the acquisition of [[Biohaven Pharma]] and its [[calcitonin gene-related peptide]] programs for $11.6 billion.<ref>{{cite web | url=https://www.biospace.com/article/releases/pfizer-completes-acquisition-of-biohaven-pharmaceuticals/?s=110 | title=Pfizer Completes Acquisition of Biohaven Pharmaceuticals | date=October 3, 2022 }}</ref><ref>{{cite web | url=https://www.businesswire.com/news/home/20220510005676/en/ | title=Pfizer to Acquire Biohaven Pharmaceuticals | date=May 10, 2022 }}</ref><ref>{{cite web | url=https://www.biospace.com/article/pfizer-drops-a-cool-11-6-billion-on-migraine-leader-biohaven-/?s=79 | title=Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven }}</ref> In August 2022, the company announced it would buy Global Blood Therapeutics for $5.4 billion, boosting Pfizer's rare disease business and helping with its aim to add $25 billion in revenue by 2030.<ref>{{Cite news |last=Rockoff |first=Jonathan D. |date=2022-08-08 |title=Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics |language=en-US |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/pfizer-reaches-5-4-billion-deal-for-global-blood-therapeutics-11659954601 |access-date=2022-08-08 |issn=0099-9660}}</ref><ref>{{Cite news |last=Reuters |date=2022-08-08 |title=Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-global-blood-therapeutics-54-bln-deal-2022-08-08/ |access-date=2022-08-08}}</ref>\n\n===Acquisition history===\n{{hidden begin|border=1px #aaa solid|title=Pfizer acquisitions|ta1=center}}\n{{Tree list}}\n*'''Pfizer''' <small>(Founded 1849 as Charles Pfizer & Company)</small>\n**[[Warner\u2013Lambert]]\n***William R. Warner <small>(Founded 1856, merged 1955)</small>\n***Lambert Pharmacal Company <small>(Merged 1955)</small>\n***Parke-Davis <small>(Founded 1860, Acq 1976)</small>\n***Wilkinson Sword <small>(Acq 1993, divested 2003)</small>\n***Agouron <small>(Acq 1999)</small>\n**[[Pharmacia]] <small>(Acq 2002)</small>\n***[[Pharmacia & Upjohn]] <small>(Merged 2000)</small>\n****[[Pharmacia]] <small>(Merged 1995)</small>\n*****Farmitalia Carlo Erba\n*****Kabi Pharmacia\n*****Pharmacia Aktiebolaget\n****[[The Upjohn Company]] <small>(Merged 1995)</small>\n****[[Monsanto]] <small>(Merged 2000, divested 2002)</small>\n****[[G.D. Searle, LLC|Searle]] <small>(Merged 2000)</small>\n**Esperion Therapeutics <small>(Acq 2003, divested 2008)</small>\n**Meridica <small>(Acq 2004)</small>\n**Vicuron Pharmaceuticals <small>(Acq 2005)</small>\n**Idun <small>(Acq 2005)</small>\n**Angiosyn <small>(Acq 2005)</small>\n**Powermed <small>(Acq 2006)</small>\n**Rinat <small>(Acq 2006)</small>\n**Coley Pharmaceutical Group <small>(Acq 2007)</small>\n**CovX <small>(Acq 2007)</small>\n**Encysive Pharmaceuticals Inc <small>(Acq 2008)</small>\n**[[Wyeth]] <small>(Acq 2009)</small>\n***[[Chef Boyardee]] <small>(Acq 1946, divested 1996 with food div)</small>\t\n***S.M.A. Corporation\n***Ayerst Laboratories <small>(Acq 1943)</small>\n***Fort Dodge Serum Company <small>(Acq 1945)</small>\n***[[Bristol-Myers]] <small>(Animal Health div)</small>\n***[[Parke-Davis]] <small>(Animal Health div)</small>\n***A.H. Robins\n***Sherwood Medical <small>(Acq 1982)</small>\n***[[Genetics Institute, Inc.]] <small>(Acq 1992)</small>\n***[[American Cyanamid]] <small>(Acq 1994)</small>\n***Lederle Laboratories\n***[[Solvay S.A.|Solvay]] <small>(Acq 1995, Animal Health div)</small>\n**[[King Pharmaceuticals]] <small>(Acq 2010)</small>\n***Monarch Pharmaceuticals, Inc.\n***King Pharmaceuticals Research and Development, Inc.\t\n***Meridian Medical Technologies, Inc.\n***Parkedale Pharmaceuticals, Inc.\n***King Pharmaceuticals Canada Inc.\n***Monarch Pharmaceuticals Ireland Limited\n**Synbiotics Corporation <small>(Acq 2011)</small>\n**Icagen <small>(Acq 2011)</small>\n**Ferrosan <small>(Consumer Health div, Acq 2011)</small>\n**Excaliard Pharmaceuticals <small>(Acq 2011)</small>\n**Alacer Corp <small>(Acq 2012)</small>\n**NextWave Pharmaceuticals, Inc <small>(Acq 2012)</small>\n**Innopharma <small>(Acq 2014)</small>\n**Redvax GmbH <small>(Acq 2014)</small>\n**Hospira <small>(Spun off from Abbott Laboratories 2004, Acq 2015)</small>\u202f\t\n***Mayne Pharma Ltd <small>(Acq 2007)</small>\n***Pliva-Croatia\t\n***[[Orchid Chemicals & Pharmaceuticals Ltd.]] <small>(Generics & Injectables div, Acq 2009)</small>\u202f\t\n***Javelin Pharmaceuticals, Inc. <small>(Acq 2010)</small>\t\n***TheraDoc <small>(Acq 2010)</small>\n***Arixa Pharmaceuticals <small>(Acq 2020)</small>\n**Anacor Pharmaceuticals<small>(Acq 2016)</small>\n**Bamboo Therapeutics <small>(Acq 2016)</small>\n**[[Medivation]] <small>(Acq 2016)</small>\n**[[AstraZeneca]] <small>(Small molecule antibiotic div, Acq 2016)</small>\n**[[Array BioPharma]] <small>(Acq 2019)</small>\n**Amplyx Pharmaceuticals <small>(Acq 2021)</small>\n**Trillium Therapeutics <small>(Acq 2021)</small>\n**[[Arena Pharmaceuticals]] <small>(Acq 2022)</small>\n**ReViral Ltd <small>(Acq 2022)</small>\n**Biohaven Pharma <small>(Acq 2022)</small>\n***Kleo Pharmaceuticals, Inc. <small>(Acq 2021)</small>\n{{Tree list/end}}\n{{hidden end}}\n\n===COVID-19 ===\nPfizer has developed and launched several products in response to the [[COVID-19 pandemic]], including the [[Pfizer\u2013BioNTech COVID-19 vaccine]] and [[Paxlovid]].\n\nIn March 2020, Pfizer joined the [[COVID-19 Therapeutics Accelerator]] funding vehicle to expedite development of [[Treatment and management of COVID-19|treatments against COVID-19]].<ref>{{Cite web |last=Staines |first=Richard |date=2020-03-26 |title=Pharma giants including Novartis collaborate on COVID-19 therapies |url=https://pharmaphorum.com/news/collaborate-covid19-therapies/ |url-status=live |archive-url=https://archive.today/20220118165943/https://pharmaphorum.com/news/collaborate-covid19-therapies/ |archive-date=January 18, 2022 |access-date=2022-06-06 |website=Pharmaphorum |language=en-GB }}</ref><ref>{{Cite web |title=Advancing research into accessible coronavirus treatments |url=https://www.therapeuticsaccelerator.org/ |url-status=live |archive-url=https://archive.today/20210707230649/https://www.therapeuticsaccelerator.org/ |archive-date=July 7, 2021 |access-date=2022-06-06 |website=COVID-19 Therapeutics Accelerator |language=en-US }}</ref> The $125 million initiative was launched by the [[Bill & Melinda Gates Foundation]] in partnership with [[Mastercard]] and [[Wellcome Trust]], with additional funding announced shortly after from [[Chan Zuckerberg Initiative]], [[Foreign, Commonwealth and Development Office|UK Foreign, Commonwealth and Development Office]] and [[Madonna]].<ref>{{Cite web |date=2020-03-10 |title=Announcing the COVID-19 Therapeutics Accelerator |url=https://www.gatesfoundation.org/ideas/articles/coronavirus-mark-suzman-therapeutics |url-status=live |archive-url=https://archive.today/20220118165008/https://www.gatesfoundation.org/ideas/articles/coronavirus-mark-suzman-therapeutics |archive-date=January 18, 2022 |access-date=2022-06-06 |website=[[Bill & Melinda Gates Foundation]] |language=en }}</ref><ref>{{Cite web |last=Au-Yeung |first=Angel |date=2020-04-03 |title=A Bill Gates-Backed Accelerator For COVID-19 Therapeutics Treatment Partners With Madonna And Mark Zuckerberg's Chan Zuckerberg Initiative |url=https://www.forbes.com/sites/angelauyeung/2020/04/03/a-bill-gates-backed-accelerator-for-covid-19-coronavirus-therapeutics-treatment-partners-with-madonna-and-mark-zuckerbergs-chan-zuckerberg-initiative/ |url-status=live |archive-url=https://archive.today/20220118165740/https://www.forbes.com/sites/angelauyeung/2020/04/03/a-bill-gates-backed-accelerator-for-covid-19-coronavirus-therapeutics-treatment-partners-with-madonna-and-mark-zuckerbergs-chan-zuckerberg-initiative/?sh=54ee18948067 |archive-date=January 18, 2022 |access-date=2022-06-06 |website=[[Forbes]] |language=en }}</ref>\n\nThe following month, the [[Foundation for the National Institutes of Health]] announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding up development of COVID-19 vaccines and pharmaceutical products.<ref>{{Cite web |title=Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) |url=https://www.nih.gov/research-training/medical-research-initiatives/activ |url-status=live |archive-url=https://archive.ph/8eMTV |archive-date=2022-01-11 |access-date=2022-06-19 |website=[[National Institutes of Health]] (NIH) |language=EN}}</ref> Pfizer joined the partnership as an industry \"leadership organization\", and participated as a collaborator in ACTIV-led clinical trials.<ref>{{Cite journal |last=University of Minnesota |date=2022-03-04 |others=International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group |title=A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04501978}}</ref><ref>{{Cite web |last=Wholley |first=David |date=2020-06-12 |title=Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) |url=https://www.bio.org/sites/default/files/2020-06/ACTIV-BIO-webinar-6-12-20-final.pdf |url-status=live |archive-url=https://web.archive.org/web/20220326054706/https://www.bio.org/sites/default/files/2020-06/ACTIV-BIO-webinar-6-12-20-final.pdf |archive-date=2022-03-26 |access-date=2022-06-18 |website=[[Biotechnology Innovation Organization]]}}</ref> CEO [[Albert Bourla]] attended the [[GAVI]] [[COVAX AMC]] 2021 Investment Opportunity Launch Event, otherwise named One World Protected, on April 15, 2021.<ref>{{Cite web |last1=U.S. Department of State |last2=USAID |last3=Gavi, the Vaccine Alliance |date=2021-04-15 |title=The Gavi COVAX AMC Investment Opportunity Launch Event Participant List |url=https://www.gavi.org/sites/default/files/covid/covax/Investment-Opportunity-Launch-Participant-List.pdf |url-status=live |archive-url=https://web.archive.org/web/20220821050428/https://www.gavi.org/sites/default/files/covid/covax/Investment-Opportunity-Launch-Participant-List.pdf |archive-date=2022-08-21 |access-date=2022-08-21 |website=[[Gavi, the Vaccine Alliance]]|author1-link=U.S. Department of State |author2-link=USAID |author3-link=Gavi, the Vaccine Alliance }}</ref>\n\nIn Canada, Pfizer endorsed the use of a [[Vaccine passports during the COVID-19 pandemic|vaccine passport]] [[mobile app]] developed by CANImmunize in order to record and track status of COVID-19 vaccination.<ref name=\":3\">{{Cite web |date=2022 |title=Partners |url=https://www.canimmunize.ca/en/partners |url-status=live |archive-url=https://web.archive.org/web/20220517111831/https://www.canimmunize.ca/en/partners |archive-date=2022-05-17 |access-date=2022-07-01 |website=[[CANImmunize]]}}</ref>\n\n==== COVID-19 pandemic and vaccine development ====\n{{See also|Pfizer\u2013BioNTech COVID-19 vaccine}}\n\n===== Initial development and testing =====\nAs the scale of the [[COVID-19 pandemic]] became apparent, Pfizer partnered with BioNTech to study and develop [[COVID-19]] mRNA vaccine candidates. Unlike many of its competitors, Pfizer took no initial research funds from the United States' [[Operation Warp Speed]] vaccine development program, instead choosing to invest roughly $2 billion of its own funds. Pfizer CEO Albert Bourla has said that he declined money from Operation Warp Speed to avoid government intervention, stating later that \"when you get money from someone that always comes with strings. They want to see how we are going to progress, what type of moves you are going to do. They want reports. And also, I wanted to keep Pfizer out of politics, by the way.\"<ref>{{Cite news |last=Czachor |first=Emily |date=2020-11-09 |title=Pfizer Avoided R&D Funding From Trump's Operation Warp Speed Because of Bureaucracy, Politics |work=[[Newsweek]] |url=https://www.newsweek.com/pfizer-avoided-rd-funding-trumps-operation-warp-speed-because-bureaucracy-politics-1546110 |access-date=2021-05-18}}</ref>\n\nIn May 2020, Pfizer began testing four different [[COVID-19 vaccine]] variations using [[lipid nanoparticle]] technology provided by Canadian biotechnology company [[Acuitas Therapeutics]].<ref name=\":22\">{{Cite web |last=Bianchini |first=Elisabetta |date=2020-11-10 |title=Acuitas Therapeutics: The Canadian technology that the Pfizer and BioNTech COVID-19 vaccine 'can't work without' |url=https://ca.news.yahoo.com/covid19-vaccine-coronavirus-canada-acuitas-therapeutics-pfizer-biontech-211410040.html |url-status=live |archive-url=https://web.archive.org/web/20220930214712/https://ca.news.yahoo.com/covid19-vaccine-coronavirus-canada-acuitas-therapeutics-pfizer-biontech-211410040.html |archive-date=2022-09-30 |access-date=2022-09-30 |website=[[Yahoo! News]] |language=en-CA}}</ref> Vaccines were injected into the first human participants in the U.S. in early May. In July 2020, Pfizer and BioNTech announced that two of the partners' four [[Messenger RNA|mRNA]] vaccine candidates had won fast track designation from the [[Food and Drug Administration|FDA]].<ref>{{Cite web |last=DeArment |first=Alaric |date=2020-07-13 |title=Pfizer, BioNTech get fast-track from FDA for Covid-19 vaccines |url=https://medcitynews.com/2020/07/pfizer-biontech-get-fast-track-from-fda-for-covid-19-vaccines/ |access-date=2020-07-15 |website=MedCity News}}</ref> The company began Phase{{nbs}}II-III testing on 30,000 people in the last week of July 2020 and was slated to be paid $1.95{{nbs}}billion for 100{{nbsp}}million doses of the vaccine by the US government.<ref>{{Cite news |title=Pfizer Beats Forecasts as Vaccine Trial Enters Final Stage |url=https://www.wsj.com/articles/pfizer-sales-fall-as-company-races-toward-covid-19-vaccine-11595936314 |website=The Wall Street Journal |date=July 29, 2020}}</ref> The U.S. deal priced two doses at $39, and the company stated that it would not lower the rates for other countries until the outbreak is no longer a pandemic.<ref>{{Cite news |title=Pfizer To Charge $39 Per Coronavirus Vaccine Course To All Developed Countries For Similar Volume Commitments As US |url=https://news.yahoo.com/pfizer-charge-39-per-coronavirus-065224983.html |work=Benzinga |publisher=[[Yahoo!]] |date=July 29, 2020}}</ref> Pfizer's CEO stated the companies in the private sector producing a vaccine should make a profit.<ref>{{Cite web |title=Pfizer CEO Says Companies Should Make Profit On Covid-19 Vaccines |url=https://www.barrons.com/articles/pfizer-ceo-says-companies-should-make-profit-on-covid-19-vaccines-51595968611 |publisher=Barron's}}</ref> In September 2020, Pfizer and BioNTech announced that they had completed talks with the European Commission to provide an initial 200{{nbsp}}million vaccine doses to the EU, with the option to supply another 100{{nbsp}}million doses at a later date.<ref>{{Cite web |last=Kilgore |first=Tomi |title=Pfizer, BioNTech conclude talks over supplying EU with SARS-CoV-2 vaccine candidate |url=https://www.marketwatch.com/story/pfizer-biontech-conclude-talks-over-supplying-eu-with-sars-cov-2-vaccine-candidate-2020-09-09 |access-date=2020-09-10 |website=MarketWatch}}</ref>\n\n===== Efficacy results and authorization =====\n{{See also|Pfizer\u2013BioNTech COVID-19 vaccine#Authorizations|}}\nOn November 9, 2020, Pfizer announced that BioNTech's COVID-19 vaccine, tested on 43,500 people, was found to be 90% effective at preventing symptomatic COVID-19.<ref>{{Cite news |date=November 9, 2020 |title=Covid vaccine: First 'milestone' vaccine offers 90% protection |work=[[BBC News]] |url=https://www.bbc.com/news/health-54873105}}</ref> The efficacy was updated to 95% a week later.<ref name=\":1\">{{Cite web |last=Kounang |first=Nadia |date=9 November 2020 |title=Pfizer and BioNTech say final analysis shows coronavirus vaccine is 95% effective with no safety concerns |url=https://www.cnn.com/2020/11/18/health/pfizer-coronavirus-vaccine-safety/index.html |access-date=9 November 2020 |website=CNN}}</ref> Akiko Iwasaki, an immunologist interviewed by the ''New York Times'', described the efficacy figure as \"really a spectacular number.\"<ref>{{Cite news |last1=Thomas |first1=Katie |last2=Gelles |first2=David |last3=Zimmer |first3=Carl |date=2020-11-09 |title=Pfizer's Early Data Shows Vaccine Is More Than 90% Effective |language=en-US |work=The New York Times |url=https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html |access-date=2021-05-18 |issn=0362-4331}}</ref> The announcement made Pfizer and BioNTech the first companies to develop and test a working vaccine for COVID-19.<ref name=\":1\" />\n\nOver the following month and a half, regulators in various countries approved Pfizer's vaccine for emergency use. The United Kingdom approved the vaccine first, on December 2,<ref>{{Cite web |last=Roberts |first=Michelle |date=2 December 2020 |title=Covid-19: Pfizer/BioNTech vaccine judged safe for use in UK |url=https://www.bbc.com/news/health-55145696 |access-date=2 December 2020 |website=[[BBC News]]}}</ref> followed by [[Bahrain]] on December 4,<ref name=\"Bahrain Approves Covid-19 Vaccine (Al Jazeera)\">{{Cite news |date=4 December 2020 |title=Bahrain becomes second country to approve Pfizer COVID-19 vaccine |work=www.aljazeera.com |publisher=Al Jazeera |url=https://www.aljazeera.com/news/2020/12/4/bahrain-becomes-second-country-to-approve-pfizer-covid-19-vaccine |access-date=11 December 2020}}</ref> Canada on December 9,<ref name=\"Canada Approves Covid-19 Vaccine (NYT)\">{{Cite news |last=Austen |first=Ian |date=9 December 2020 |title=Canada Approves Vaccine and Could Start Shots Next Week |work=The New York Times |url=https://www.nytimes.com/2020/12/09/world/americas/canada-vaccine-approve.html |access-date=11 December 2020}}</ref> and Saudi Arabia on December 10.<ref name=\"Saudi Arabia Approves Covid-19 Vaccine, Bahrain To Distribute Free to Public (KTLA)\">{{Cite news |date=11 December 2020 |title=Saudi Arabia approves Pfizer COVID-19 vaccine as Bahrain plans to give the public free shots |work=KTLA |url=https://ktla.com/news/nationworld/saudi-arabia-approves-pfizer-covid-19-vaccine-as-bahrain-plans-to-give-the-public-free-shots/ |access-date=11 December 2020}}</ref> On December 10, 2020, the United States FDA held an advisory committee meeting to discuss authorization of the vaccine.<ref name=\"US FDA Advisory Panel Backs Covid-19 Vaccine Approval (Reuters)\">{{Cite news |last=Steenhuysen |first=Manas Mishra, Julie |date=11 December 2020 |title=U.S. FDA advisers overwhelmingly back authorizing Pfizer\u2013BioNTech COVID-19 vaccine |work=Reuters |url=https://www.reuters.com/article/health-coronavirus-pfizer-vaccine/us-fda-advisers-wrestle-with-ethical-issues-linked-to-authorizing-pfizers-covid-19-vaccine-idUSKBN28K1O5 |access-date=11 December 2020}}</ref> The next day, the US officially became the 5th country to approve use of Pfizer's vaccine under an Emergency Use Authorization (EUA), with an independent panel voting 17\u20134 in support of approval.<ref name=\"US FDA Advisory Panel Backs Covid-19 Vaccine Approval (Reuters)\" /><ref>{{Cite news |last1=Thomas |first1=Katie |last2=LaFraniere |first2=Sharon |last3=Weiland |first3=Noah |last4=Goodnough |first4=Abby |last5=Haberman |first5=Maggie |date=2020-12-12 |title=F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away |work=The New York Times |url=https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html |access-date=2020-12-12 |issn=0362-4331}}</ref> On December 14, Singapore became one of the first in Asia to approve the vaccine through the [[Health Sciences Authority]].<ref>{{Cite news |last=Abdullah |first=Zhaki |title=Pfizer\u2013BioNTech COVID-19 vaccine approved by Singapore, first shipment expected by end-December |url=https://www.channelnewsasia.com/news/singapore/singapore-approves-pfizer-biontech-covid-19-vaccine-phase-3-13769570 |date=December 14, 2020 |website=CNA}}</ref> On December 21, the [[European Medicines Agency]] (EMA) recommended granting a conditional marketing authorisation for the vaccine in the [[European Union]], under the brand name \"Comirnaty.\"<ref>{{cite news |url=https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu |title=EMA recommends first COVID-19 vaccine for authorisation in the EU |website=[[Europa (web portal)|Europa]] |date=December 21, 2020}}</ref>\n\n===== Manufacturing and distribution =====\n{{See also|Pfizer\u2013BioNTech COVID-19 vaccine#Manufacturing|Deployment of COVID-19 vaccines}}\nAs of early May 2021, Pfizer and BioNTech had manufactured at least 430 million vaccine doses, which have been distributed to 91 countries and territories. The companies have said they expect to manufacture nearly 3 billion total vaccine doses in 2021.<ref>{{Cite news |last=Higgins-Dunn |first=Noah |date=2021-05-04 |title=BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says |work=[[FiercePharma]] |url=https://www.fiercepharma.com/pharma/thanks-to-revved-up-manufacturing-biontech-ceo-estimates-3b-covid-vaccine-doses-2021 |access-date=2021-05-18}}</ref> Pfizer provided 0.9% [[Sodium chloride solution|Sodium chloride]] Injection USP diluent for use with the [[Pfizer\u2013BioNTech COVID-19 vaccine]] under the name of its subsidiary, [[Hospira]].<ref>{{Cite web |date=December 2021 |title=Package Insert - Comirnaty |url=https://www.fda.gov/media/151707/download |url-status=live |access-date=2022-05-24 |website=[[U.S. Food and Drug Administration]]}}</ref> Pfizer also purchased large quantities of single-use medical and [[surgical gloves]] and protective bodysuits from [[Ansell]] during the process, contributing to a doubling of the supplier's manufacturing capacity.<ref>{{Cite web |last=Evans |first=Simon |date=2021-02-15 |title=Ansell doubles production as extraordinary demand to stay |url=https://www.afr.com/companies/manufacturing/ansell-doubles-production-as-extraordinary-demand-to-stay-20210215-p572p0 |url-status=live |archive-url=https://web.archive.org/web/20220701194749/https://www.afr.com/companies/manufacturing/ansell-doubles-production-as-extraordinary-demand-to-stay-20210215-p572p0 |archive-date=2022-07-01 |access-date=2022-07-01 |website=[[Australian Financial Review]] |language=en}}</ref>\n\n===== Controversy =====\nIn February 2021, after a year long investigation relying on unnamed officials, Pfizer was accused by [[The Bureau of Investigative Journalism]] (TBIJ) of employing \"high-level bullying\" against at least two [[Latin America]]n countries during negotiations to acquire COVID-19 vaccines, including requesting that the countries put sovereign assets as [[Collateral (finance)|collateral]] for payments.<ref name=\"bullied\">{{Cite news |title=Investigation: Drugmaker 'bullied' Latin American nations |url=https://www.aljazeera.com/news/2021/3/11/investigation-pfizer-bullied-latin-american-nations |website=[[Al Jazeera English]] |date=March 11, 2021}}</ref> According to TBIJ, these negotiation tactics resulted in a months long delay in Pfizer reaching a vaccine agreement with one country and a complete failure to reach agreements with two other countries, including [[Argentina]] and Brazil.<ref name=\"bullied\"/>\n\nOn 2 November 2021, TBMJ published an article after obtaining information from a [[whistleblower]] from the Ventavia Research Group. Ventavia was hired by Pfizer as a research subcontractor. The company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in [[Pfizer\u2013BioNTech COVID-19 vaccine#Clinical trials|Pfizer's pivotal phase III trial]]. The regional director, Brook Jackson, emailed a complaint to the US [[Food and Drug Administration]] (FDA). Ventavia fired her later the same day.<ref>{{cite news |last1=Thacker |first1=Paul |title=Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial |url=https://www.bmj.com/content/375/bmj.n2635 |access-date=2 November 2021 |publisher=thebmj}}</ref> The [[European Medicines Agency]] (EMA) stated in a response to the [[European Parliament]], that \"the deficiencies identified do not jeopardize the quality and integrity of the data from the main Comirnaty trial and have no impact on the benefit-risk assessment or on the conclusions on the safety, effectiveness and quality of the vaccine\".<ref>{{Cite web |url=https://www.ema.europa.eu/en/documents/other/ema-reply-letter-members-european-parliament-ms-m-rivasi-mr-p-pedicini-ms-t-metz-concerning-covid-19_en.pdf |title=Reply letter on the Integrity of clinical data, additional clinical trials and studies, pharmacovigilance and mRNA COVID-19 vaccine safety |author=[[European Medicines Agency]] |date=3 December 2021 |access-date=2 February 2022}}</ref>\n\nOn 10 October 2022, during a session of the [[European Parliament]]'s Special Committee on the COVID-19 Pandemic, Pfizer executive Janine Small testified that the company had not evaluated their [[Pfizer\u2013BioNTech COVID-19 vaccine|COVID-19 vaccine]] for its ability to reduce transmission of the [[SARS-CoV-2]] virus prior to its release to the general public.<ref>{{Cite web |date=2022-10-10 |title=Special Committee on COVID-19 pandemic |url=https://multimedia.europarl.europa.eu/en/webstreaming/special-committee-on-covid-19-pandemic_20221010-1430-COMMITTEE-COVI |url-status=live |archive-url=https://web.archive.org/web/20221014010053/https://multimedia.europarl.europa.eu/en/webstreaming/special-committee-on-covid-19-pandemic_20221010-1430-COMMITTEE-COVI |archive-date=2022-10-14 |access-date=2022-10-14 |website=[[European Parliament]] Multimedia Centre |language=en}}</ref><ref>{{Cite web |last=TN World Desk |date=2022-10-13 |title=Pfizer admits it did not know whether its Covid vaccine prevented transmission of virus when rollout began |url=https://www.timesnownews.com/world/pfizer-admits-it-did-not-know-its-covid-vaccine-prevented-transmission-of-virus-when-rollout-began-article-94836651 |url-status=live |archive-url=http://archive.today/2022.10.13-205522/https://www.timesnownews.com/world/pfizer-admits-it-did-not-know-its-covid-vaccine-prevented-transmission-of-virus-when-rollout-began-article-94836651 |archive-date=2022-10-13 |access-date=2022-10-14 |website=[[TimesNow]] |language=en}}</ref> Dutch MEP [[Rob Roos]] described the admission as \"scandalous\".<ref>{{Cite web |last=Chung |first=Frank |date=2022-10-13 |title=Pfizer did not know whether Covid vaccine stopped transmission before rollout, executive admits |url=https://www.news.com.au/technology/science/human-body/pfizer-did-not-know-whether-covid-vaccine-stopped-transmission-before-rollout-executive-admits/news-story/f307f28f794e173ac017a62784fec414 |url-status=live |archive-url=https://web.archive.org/web/20221014110736/https://www.news.com.au/technology/science/human-body/pfizer-did-not-know-whether-covid-vaccine-stopped-transmission-before-rollout-executive-admits/news-story/f307f28f794e173ac017a62784fec414 |archive-date=2022-10-14 |access-date=2022-10-14 |website=[[News.com.au]]}}</ref> CEO [[Albert Bourla]] was slated to attend, but withdrew.<ref>{{Cite web |last=Bauer-Babef |first=Clara |date=2022-10-12 |title=Pfizer remains discreet about COVID vaccine purchase contracts |url=https://www.euractiv.com/section/coronavirus/news/pfizer-remains-discreet-about-covid-vaccine-purchase-contracts/ |url-status=live |archive-url=https://web.archive.org/web/20221013183554/https://www.euractiv.com/section/coronavirus/news/pfizer-remains-discreet-about-covid-vaccine-purchase-contracts/ |archive-date=2022-10-13 |access-date=2022-10-14 |website=[[Euractiv]] |language=en-GB}}</ref> Roos' statements in turn have been described as \"misleading\".<ref>{{Cite web | date=2022-10-11 |title=Scientific studies show that the Pfizer-BioNTech COVID-19 vaccine reduces transmission; claim by Rob Roos is misleading |url=https://healthfeedback.org/claimreview/scientific-studies-show-pfizer-biontech-covid-19-vaccine-reduces-transmission-claim-rob-roos-misleading|url-status=live |archive-url=https://web.archive.org/web/20221018181058/https://healthfeedback.org/claimreview/scientific-studies-show-pfizer-biontech-covid-19-vaccine-reduces-transmission-claim-rob-roos-misleading/ |archive-date=2022-10-18 |access-date=2022-10-18 |website=[[Health Feedback]] |language=en-GB}}</ref>\n\n==== Development of oral antivirals ====\nIn November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as [[Nirmatrelvir/ritonavir|Paxlovid]]. In January 2022, the Pfizer CEO [[Albert Bourla]] confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, [[Novasep]]. He also said the COVID vaccine was \"safe and efficient\" for children.<ref>{{Cite web |url=https://www.israelnationalnews.com/news/320624 |title=Pfizer CEO: Current wave will be last with so many restrictions |access-date=17 January 2021 |website=[[Israel National News]]}}</ref><ref>{{Cite web |url=https://www.livemint.com/companies/news/pfizer-ceo-shares-some-good-news-on-covid-but-cautions-virus-could-circulate-for-years-11642405004050.html |title=Pfizer CEO shares some good news on covid but cautions virus could circulate for years |access-date=17 January 2021 |website=[[Mint (newspaper)|Mint]]}}</ref> In May 2022, reports emerged of patients experiencing \"rebound\" symptoms after completing a five-day course of Paxlovid.<ref>{{Cite news |last=Hopkins |first=Jared S. |date=2022-05-10 |title=Some Covid-19 Patients Relapse After Taking Paxlovid, Puzzling Doctors |language=en-US |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/some-covid-19-patients-relapse-after-taking-paxlovid-puzzling-doctors-11652186194 |access-date=2022-05-16 |issn=0099-9660}}</ref> The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations.<ref>{{Cite journal |last=Farley |first=John |date=2022-05-04 |title=FDA Updates on Paxlovid for Health Care Providers |url=https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers |journal=[[Food and Drug Administration]] |language=en}}</ref> U.S. President [[Joe Biden]] and Dr. [[Anthony Fauci]] were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.<ref>{{Cite web |last=Samuels |first=Fionna M. D. |date=2022-08-08 |title=What Is Paxlovid Rebound, and How Common Is It? |url=https://www.scientificamerican.com/article/what-is-paxlovid-rebound-and-how-common-is-it/ |url-status=live |archive-url=https://archive.ph/AvXx0 |archive-date=2022-08-18 |access-date=2022-08-22 |website=[[Scientific American]] |language=en}}</ref>\n\n==Legal issues==\n===Aggressive pharmaceutical marketing===\n{{See also|List of largest pharmaceutical settlements|Franklin v. Parke-Davis}}\nPfizer has been accused of aggressive [[pharmaceutical marketing]].<ref>{{Cite news |url=https://nymag.com/nymetro/health/features/3122/ |title=Inside the Happiness Business |last=Kirkpatrick |first=David D. |work=[[New York (magazine)|New York]] |date=May 15, 2000}}</ref><ref>{{Cite journal |last=Oldani |first=Michael |date=2002 |title=Tales from the Script |url=https://digitalassets.lib.berkeley.edu/anthpubs/ucb/text/kas087-006.pdf |journal=Kroeber Society Papers |volume=87 |pages=147\u2013176 |via=University of California Berkeley}}</ref><ref>{{Cite journal |last=Oldani |first=Michael J. |date=2004 |title=Thick Prescriptions: Toward an Interpretation of Pharmaceutical Sales Practices |journal=Medical Anthropology Quarterly |volume=18 |issue=3 |pages=325\u2013356 |doi=10.1525/maq.2004.18.3.325 |issn=1548-1387 |pmid=15484967}}</ref>\n\n====Illegal marketing of gabapentin for off-label uses====\nIn 1993, the [[Food and Drug Administration]] (FDA) approved [[gabapentin]] only for treatment of [[seizures]]. [[Warner\u2013Lambert]], which merged with Pfizer in 2000, used [[continuing medical education]] and [[medical research]], sponsored articles about the drug for the medical literature, and alleged suppression of unfavorable study results, to promote gabapentin. Within five years, the drug was being widely used for [[off-label use]]s such as treatment of pain and psychiatric conditions. Warner\u2013Lambert admitted to violating FDA regulations by promoting the drug for pain, psychiatric conditions, migraine, and other unapproved uses.<ref>{{Cite journal |vauthors=Steinman MA, Bero LA, Chren MM, Landefeld CS |date=August 2006 |title=Narrative review: the promotion of gabapentin: an analysis of internal industry documents |journal=[[Annals of Internal Medicine]] |volume=145 |issue=4 |pages=284\u201393 |doi=10.7326/0003-4819-145-4-200608150-00008 |pmid=16908919 |doi-access=free}}</ref> In 2004, the company paid $430{{nbsp}}million in one of the largest settlements to resolve criminal and civil health care liability charges. It was the first off-label promotion case successfully brought under the [[False Claims Act]].<ref>{{Cite journal |last=Henney JE |date=August 2006 |title=Safeguarding patient welfare: who's in charge? |journal=[[Annals of Internal Medicine]] |volume=145 |issue=4 |pages=305\u20137 |doi=10.7326/0003-4819-145-4-200608150-00013 |pmid=16908923 |s2cid=39262014}}</ref> A Cochrane review concluded that gabapentin is ineffective in migraine prophylaxis.<ref>{{Cite journal |vauthors=Mulleners WM, McCrory DC, Linde M |date=August 2014 |title=Antiepileptics in migraine prophylaxis: An updated Cochrane review |journal=Cephalalgia |volume=35 |issue=1 |pages=51\u201362 |doi=10.1177/0333102414534325 |pmid=25115844 |s2cid=43079346}}</ref> The [[American Academy of Neurology]] rates it as having unproven efficacy, while the [[Canadian Headache Society]] and the [[European Federation of Neurological Societies]] rate its use as being supported by moderate and low-quality evidence.<ref>{{Cite journal |vauthors=Loder E, Burch R, Rizzoli P |date=June 2012 |title=The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines |journal=Headache |volume=52 |issue=6 |pages=930\u201345 |doi=10.1111/j.1526-4610.2012.02185.x |pmid=22671714 |doi-access=free |s2cid=540800}}</ref>\n\n====Illegal marketing of Bextra====\nIn September 2009, Pfizer pleaded guilty to the illegal marketing of [[arthritis]] drug [[valdecoxib]] (''Bextra'') and agreed to a $2.3{{nbsp}}billion settlement, the largest [[health care fraud]] settlement at that time.<ref>{{cite web |title=Justice Department Announces Largest Health Care Fraud Settlement in Its History |url=https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history |publisher=[[United States Department of Justice]] |access-date=2022-05-15 |archive-url=https://web.archive.org/web/20220512181155/https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history |archive-date=May 12, 2022 |date=2009-09-09 |quote=American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together \"Pfizer\") have agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced today.}}</ref> Pfizer promoted the sale of the drug for several uses and dosages that the [[Food and Drug Administration]] specifically declined to approve due to safety concerns. The drug was pulled from the market in 2005.<ref>{{Cite news |url=https://www.nytimes.com/2009/09/03/business/03health.html |title=Pfizer pays $2.3 billion to settle marketing case |first=Gardiner |last=Harris |work=[[The New York Times]] |date=September 2, 2009 |url-access=limited}}</ref> It was Pfizer's fourth such settlement in a decade.<ref name=Settle/><ref name=Improper>{{Cite news |last=Johnson |first=Carrie |date=September 3, 2009 |title=In Settlement, A Warning To Drugmakers: Pfizer to Pay Record Penalty In Improper-Marketing Case |newspaper=[[The Washington Post]] |url=https://www.washingtonpost.com/wp-dyn/content/article/2009/09/02/AR2009090201449_pf.html}}</ref><ref name=fine/> The payment included $1.195{{nbsp}}billion in criminal penalties for felony violations of the [[Federal Food, Drug, and Cosmetic Act]], and $1.0{{nbsp}}billion to settle allegations it had illegally promoted the drugs for uses that were not approved by the [[Food and Drug Administration]] (FDA) leading to violations under the [[False Claims Act]] as reimbursements were requested from Federal and State programs. The criminal fine was the largest ever assessed in the United States to date.<ref name=Settle>{{Cite news |last=Harris |first=Gardiner |title=Pfizer Pays $2.3 billion to Settle Marketing Case |work=[[The New York Times]] |url=https://www.nytimes.com/2009/09/03/business/03health.html |date=September 3, 2009}}</ref><ref name=Improper/><ref name=fine>{{Cite news |title=Pfizer agrees record fraud fine |work=[[BBC News]] |url=http://news.bbc.co.uk/2/hi/business/8234533.stm |date=September 2, 2009}}</ref> Pfizer entered a [[corporate integrity agreement]] with the [[Office of Inspector General (United States)|Office of Inspector General]] that required it to make substantial structural reforms within the company, and publish to its website its post approval commitments and a searchable database of all payments to physicians made by the company.<ref>{{Cite web |title=Corporate Integrity Agreement between the Office of the Inspector General of the Department of Health and Human Services and Pfizer Inc. |url=https://oig.hhs.gov/fraud/cia/agreements/pfizer_inc.pdf |website=[[Office of Inspector General (United States)|Office of Inspector General]] |date=August 31, 2009 |url-status=live |archive-url=https://web.archive.org/web/20110715112330/http://oig.hhs.gov/fraud/cia/agreements/pfizer_inc.pdf |archive-date=July 15, 2011}}</ref>\n\n====Termination of Peter Rost====\n[[Peter Rost (doctor)|Peter Rost]] was vice president in charge of the [[endocrinology]] division at [[Pharmacia]] before its acquisition by Pfizer. During that time he raised concerns internally about [[kickback (bribery)|kickbacks]] and off-label marketing of Genotropin, Pharmacia's [[human growth hormone]] drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Pfizer. Pfizer kept him employed, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him, and he filed a wrongful termination suit against Pfizer. Pfizer won a summary dismissal of the case, with the court ruling that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblower activities.<ref>{{Cite web |title=ROST v. PFIZER, INC. |publisher=Casetext |url=https://casetext.com/case/rost-v-pfizer-2}}</ref><ref>{{Cite news |url=https://www.nytimes.com/2005/06/08/business/at-pfizer-the-isolation-increases-for-a-whistleblower.html |title=At Pfizer, the Isolation Increases for a Whistle-Blower |first=Alex |last=Berenson |authorlink=Alex Berenson |work=[[The New York Times]] |date=June 8, 2005 |url-access=limited}}</ref>\n\n====Illegal marketing of Rapamune====\nA \"whistleblower suit\" was filed in 2005 against [[Wyeth]], which was acquired by Pfizer in 2009, alleging that the company illegally marketed [[sirolimus]] (''Rapamune'') for [[off-label use]]s, targeted specific doctors and medical facilities to increase sales of Rapamune, tried to get transplant patients to change from their transplant drugs to Rapamune, and specifically targeted [[African-Americans]]. According to the whistleblowers, Wyeth also provided doctors and hospitals that prescribed the drug with kickbacks such as grants, donations, and other money.<ref>{{Cite news |url=https://www.fiercepharma.com/pharma/congress-joins-probe-into-wyeth-s-rapamune-marketing |title=Congress joins probe into Wyeth's Rapamune marketing |first=Tracy |last=Staton |work=[[FiercePharma]] |date=June 14, 2010}}</ref> In 2013, the company pleaded guilty to criminal mis-branding violations under the [[Federal Food, Drug, and Cosmetic Act]]. By August 2014, it had paid $491{{nbsp}}million in civil and criminal penalties related to Rapamune.<ref>{{Cite news |url=https://www.fiercepharma.com/regulatory/pfizer-settles-more-off-label-marketing-cases-tied-to-rapamune |title=Pfizer settles more off-label marketing cases tied to Rapamune |first=Eric |last=Palmer |work=[[FiercePharma]] |date=June 14, 2010}}</ref>\n\n====Illegal marketing====\nIn June 2010, health insurance network [[Blue Cross Blue Shield]] (BCBS) filed a lawsuit against Pfizer for allegedly illegally marketing drugs Bextra, Geodon and Lyrica. BCBS alleged that Pfizer used kickbacks and wrongly persuaded doctors to prescribe the drugs.<ref>{{Cite news |title=Blue Cross Names and Shames Pfizer Execs Linked to Massages-for-Prescriptions Push |url=https://www.cbsnews.com/news/blue-cross-names-and-shames-pfizer-execs-linked-to-massages-for-prescriptions-push/ |first=Jim |last=Edwards |work=[[CBS News]] |date=June 10, 2010}}</ref><ref>{{Cite news |url=https://www.bizjournals.com/austin/stories/2010/06/07/daily52.html |title=Blue Cross Blue Shield of Texas sues Pfizer |last=Bounds |first=Jeff |work=[[American City Business Journals]] |date=June 10, 2010}}</ref> According to the lawsuit, Pfizer handed out 'misleading' materials on [[off-label use]]s, sent over 5,000 doctors on trips to the [[Caribbean]] or around the United States, and paid them $2,000 honoraria in return for listening to lectures about Bextra.<ref>{{Cite news |url=https://www.fiercepharma.com/pharma/bcbs-names-pfizer-managers-kickback-suit |title=BCBS names Pfizer managers in kickback suit |work=[[FiercePharma]] |first=Tracy |last=Staton |date=June 11, 2010}}</ref><ref>{{Cite news |url=https://www.dallasnews.com/business/2010/06/11/blue-cross-blue-shield-of-texas-sues-pfizer-over-drug-marketing/ |title=Blue Cross Blue Shield of Texas sues Pfizer over drug marketing |work=[[The Dallas Morning News]] |date=June 11, 2010 |url-access=subscription}}</ref> Despite Pfizer's claims that \"the company's intent was pure\" in fostering a legal exchange of information among doctors, an internal marketing plan revealed that Pfizer intended to train physicians \"to serve as public relations spokespeople.\"<ref name=toobig/> The case was settled in 2014 for $325{{nbsp}}million.<ref>{{Cite news |title=Pfizer Agrees to $325 Million Neurontin Marketing Accord |url=https://www.bloomberg.com/news/2014-06-02/pfizer-agrees-to-325-million-settlment-over-neurontin.html |first=Christie |last=Smythe |work=[[Bloomberg News]] |date=June 2, 2014 |url-access=subscription}}</ref> Fearing that Pfizer is \"[[too big to fail]]\" and that prosecuting the company would result in disruptions to [[Medicare (United States)|Medicare]] and [[Medicaid]], federal prosecutors instead charged a subsidiary of a subsidiary of a subsidiary of Pfizer, which is \"nothing more than a shell company whose only function is to plead guilty.\"<ref name=toobig>{{cite news |url=https://edition.cnn.com/2010/HEALTH/04/02/pfizer.bextra/index.html |title=Feds found Pfizer too big to nail |last1=Griffin |first1=Drew |last2=Segal |first2=Andy |work=[[CNN]] |date=April 2, 2010}}</ref>\n\n===Removal of ads after unflattering article===\nAccording to ''[[Harper's Magazine]]'' publisher [[John R. MacArthur]], Pfizer withdrew \"between $400,000 and a million dollars\" worth of ads from ''[[Harper's Magazine]]'' following an unflattering article on depression medication.<ref>{{Cite news |last=Petrovich |first=Dushko |title=The Art of Making Magazines edited by Victor S. Navasky and Evan Cornog |url=https://www.bookforum.com/culture/-11264 |work=[[Bookforum]] |date=March 15, 2013}}</ref>\n\n===Quigley Company asbestos===\nThe Quigley Company, which sold [[asbestos]]-containing insulation products until the early 1970s, was acquired by Pfizer in 1968. In June 2013, asbestos victims and Pfizer negotiated a settlement that required Pfizer to pay a total of $964{{nbsp}}million: $430{{nbsp}}million to 80% of existing plaintiffs and place an additional $535{{nbsp}}million into a settlement trust that will compensate future plaintiffs as well as the remaining 20% of plaintiffs with claims against Pfizer and Quigley. Of that $535{{nbsp}}million, $405{{nbsp}}million is in a 40-year note from Pfizer, while $100{{nbsp}}million is from insurance policies.<ref>{{Cite news |url=https://www.theday.com/article/20130627/BIZ03/306279581 |title=Pfizer to pay $958M to end asbestos litigation |first=Tiffany |last=Kary |agency=[[Bloomberg News]] |date=June 27, 2013}}</ref>\n\n===Shiley defective heart valves===\nPfizer purchased Shiley in 1979, at the onset of its Convexo-Concave valve ordeal, involving the [[Bjork\u2013Shiley valve]]. Approximately 500 people died when defective [[heart valve]]s fractured and, in 1994, Pfizer agreed to pay $10.75{{nbsp}}million to settle claims by the [[United States Department of Justice]] that the company lied to get approval for the valves.<ref>{{Cite news |url=https://www.nytimes.com/1994/07/02/business/pfizer-unit-to-settle-charges-of-lying-about-heart-valve.html |title=Pfizer Unit to Settle Charges Of Lying About Heart Valve |first=Barry |last=Meier |work=The New York Times |authorlink=Barry Meier |date=July 2, 1994 |url-access=limited}}</ref>\n\n===Firing of employee that filed suit===\nA federal lawsuit was filed by a scientist claiming she got an infection by a genetically modified [[lentivirus]] while working for Pfizer, resulting in intermittent [[paralysis]].<ref>{{Cite news |title=Ex-Pfizer Worker Cites Genetically Engineered Virus In Lawsuit Over Firing |url=https://www.courant.com/news/connecticut/hc-xpm-2010-03-14-hc-pfizer-virus-lawsuit-0314-artmar14-story.html |work=[[Hartford Courant]] |date=March 14, 2010 |url-status=live |archive-url=https://archive.today/20120728144301/http://www.courant.com/news/connecticut/hc-pfizer-virus-lawsuit-0314.artmar14,0,5614508,print.story |archive-date=July 28, 2012}}</ref> A judge dismissed the case citing a lack of evidence that the illness was caused by the virus but the jury ruled that by firing the employee, Pfizer violated laws protecting [[freedom of speech]] and [[whistleblower]]s and awarded her $1.37{{nbsp}}million.<ref>{{Cite news |title=A Pfizer Whistle-Blower Is Awarded $1.4 Million |url=https://www.nytimes.com/2010/04/03/business/03pfizer.html |first1=Andrew |last1=Pollack |first2=Duff |last2=Wilson |authorlink2=Duff Wilson |work=[[The New York Times]] |date=April 2, 2010 |url-access=limited}}</ref>\n\n===Celebrex intellectual property===\n[[Brigham Young University]] (BYU) said a professor of chemistry, Dr. [[Daniel L. Simmons]], discovered an enzyme in the 1990s that led towards development of [[Celebrex]]. BYU was originally seeking a 15% royalty on sales, equating to $9.7{{nbsp}}billion. A research agreement had been made between BYU and [[Monsanto]], whose pharmaceutical business was later acquired by Pfizer, to develop a better [[aspirin]]. The enzyme Dr. Simmons claims to have discovered would induce pain and inflammation while causing gastrointestinal problems and Celebrex is used to reduce those issues. A six-year battle ensued because BYU claimed that Pfizer did not give Dr. Simmons credit or compensation, while Pfizer claimed that it had met all obligations regarding the Monsanto agreement. In May 2012, Pfizer settled the allegations, agreeing to pay $450{{nbsp}}million.<ref>{{cite news |url=https://www.nytimes.com/2012/05/02/health/pfizer-settles-byu-lawsuit-over-development-of-celebrex.html |title=Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex |agency=[[Associated Press]] |work=[[The New York Times]] |date=May 1, 2012 |url-access=limited}}</ref>\n\n===Nigeria Trovafloxacin lawsuit===\n{{main|Abdullahi v. Pfizer, Inc.}}\nIn 1996, an outbreak of measles, cholera, and bacterial meningitis occurred in Nigeria. Pfizer representatives and personnel from a contract research organization (CRO) traveled to [[Kano (city)|Kano]] to set up a clinical trial and administer an experimental [[antibiotic]], [[trovafloxacin]], to approximately 200 children.<ref>{{Citation |last=Oldani |first=Michael |title=The SAGE Encyclopedia of Pharmacology and Society |date=2016 |pages=1444\u20131447 |chapter=Trovafloxacin (Trovan) Controversy |chapter-url=http://sk.sagepub.com/reference/the-sage-encyclopedia-of-pharmacology-and-society/i11727.xml |publisher=SAGE Publications, Inc. |doi=10.4135/9781483349985.n409 |isbn=9781483350004 |access-date=2019-01-21}}</ref> Local Kano officials reported that more than fifty children died in the experiment, while many others developed mental and physical deformities.<ref>{{Cite news |url=http://news.bbc.co.uk/2/hi/africa/6768799.stm |last=Murray |first=Senan |title=Anger at deadly Nigerian drug trials |work=[[BBC News]] |date=June 20, 2007}}</ref> The nature and frequency of both fatalities and other adverse outcomes were similar to those historically found among pediatric patients treated for meningitis in sub-Saharan Africa.<ref>{{Cite journal |vauthors=Ramakrishnan M, Ulland AJ, Steinhardt LC, Mo\u00efsi JC, Were F, Levine OS |year=2009 |title=Sequelae due to bacterial meningitis among African children: a systematic literature review |journal=[[BMC Medicine]] |volume=7 |page=47 |doi=10.1186/1741-7015-7-47 |pmc=2759956 |pmid=19751516}}</ref> In 2001, families of the children, as well as the governments of Kano and Nigeria, filed lawsuits regarding the treatment.<ref>{{Cite news |url=http://news.bbc.co.uk/2/hi/business/1517171.stm |title=Nigerians sue Pfizer over test deaths |work=[[BBC News]] |date=August 30, 2001}}</ref> According to ''[[Democracy Now!]]'', \"[r]esearchers did not obtain signed consent forms, and medical personnel said Pfizer did not tell parents their children were getting the experimental drug.\"<ref name=\"DN\">{{Cite news |url=https://www.democracynow.org/2010/12/17/wikileaks_cables_pfizer_targeted_nigerian_attorney |title=WikiLeaks Cables: Pfizer Targeted Nigerian Attorney General to Undermine Suit over Fatal Drug Tests |work=[[Democracy Now!]] |date=December 17, 2010}}</ref> The lawsuits also accused Pfizer of using the outbreak to perform unapproved human testing, as well as allegedly under-dosing a control group being treated with traditional antibiotics in order to skew the results of the trial in favor of Trovan. Nigerian medical personnel as well as at least one Pfizer physician said the trial was conducted without regulatory approval.<ref>{{Cite news |url=https://www.washingtonpost.com/wp-dyn/content/article/2006/05/06/AR2006050601338.html |title=Panel Faults Pfizer in '96 Clinical Trial In Nigeria |newspaper=[[The Washington Post]] |date=May 7, 2006}}</ref><ref>{{Cite news |url=https://www.cbsnews.com/news/pfizer-bribed-nigerian-officials-in-fatal-drug-trial-ex-employee-claims/ |title=Pfizer Bribed Nigerian Officials in Fatal Drug Trial, Ex-Employee Claims |first=Jim |last=Edwards |work=[[CBS News]] |date=February 10, 2011}}</ref>\n\nIn 2007, Pfizer published a Statement of Defense letter.<ref>{{Cite web |title=Trovan, Kano State Civil Case \u2013 Statement Of Defense |url=https://cdn.pfizer.com/pfizercom/news/trovan_statement_defense_summary.pdf |publisher=Pfizer |date=July 2007}}</ref> The letter stated that the drug's oral form was safer and easier to administer, that Trovan had been used safely in more than five thousand Americans prior to the Nigerian trial, that mortality in the patients treated by Pfizer was lower than that observed historically in African meningitis epidemics, and that no unusual side effects, unrelated to meningitis, were observed after four weeks.{{citation needed|date=October 2022}}\n\nIn June 2010, the US Supreme Court rejected Pfizer's appeal against a ruling allowing lawsuits by the Nigerian families to proceed.<ref>{{Cite news |url=http://news.bbc.co.uk/2/hi/world/us_and_canada/10454982.stm |title=Pfizer-Nigeria appeal dismissed |work=[[BBC News]] |date=June 29, 2010}}</ref>\n\nIn December 2010, a [[United States diplomatic cables leak]] was released by [[WikiLeaks]] indicating that Pfizer hired investigators to find evidence of corruption against Nigerian attorney general Aondoakaa to persuade him to drop legal action.<ref>{{Cite news |last=Boseley |first=Sarah |date=December 9, 2010 |title=WikiLeaks cables: Pfizer 'used dirty tricks to avoid clinical trial payout' |work=The Guardian |location=London |url=https://www.theguardian.com/business/2010/dec/09/wikileaks-cables-pfizer-nigeria}}</ref> ''[[The Washington Post]]'' reporter Joe Stephens, who helped break the story in 2000, called these actions \"dangerously close to blackmail\".<ref name=DN/> In response, the company released a press statement describing the allegations as \"preposterous\" and saying that it acted in good faith.<ref>{{Cite press release |url=https://cdn.pfizer.com/pfizercom/news/the_guardian_nigeria_120910.pdf |title=Pfizer Statement Regarding Article In The Guardian |publisher=Pfizer |date=December 9, 2010}}</ref> Aondoakka, who had allegedly demanded bribes from Pfizer in return for a settlement of the case,<ref>{{Cite news |url=https://www.cbsnews.com/news/in-defense-of-blackmail-why-shouldnt-pfizer-dig-dirt-on-crooked-pols/ |title=In Defense of Blackmail: Why Shouldn't Pfizer Dig Dirt on Crooked Pols? |first=Jim |last=Edwards |work=[[CBS News]] |date=January 4, 2011}}</ref> was declared unfit for office and had his U.S. visa revoked in association with corruption charges in 2010.<ref>{{Cite web |title=Michael Aondoakaa \"Unfit\" To Remain SAN, Says CDHR In High-Powered Petition |url=http://saharareporters.com/2010/07/19/michael-aondoakaa-%E2%80%9Cunfit%E2%80%9D-remain-san-says-cdhr-high-powered-petition |website=Sahara Reporters}}</ref><ref>{{Cite web |title=Wikileaks on Nigeria's Corrupt Oil Sales at NNPC, Shell, US Ambassador |date=December 12, 2010 |url=http://usafricaonline.com/2010/12/12/wikileaks-on-nigerias-oil-corruption-nnpc-shell-us-ambassador-attorney-general-aondoakaa/}}</ref>\n\nThe lawsuits were eventually settled out of court. Pfizer committed to paying US$35 million \"to compensate the families of children in the study\", another US$30 million to \"support healthcare initiatives in Kano\", and 10 million to cover legal costs. Payouts began in 2011.<ref>{{cite journal |last1=Lenzer |first1=J. |title=Pfizer settles with victims of Nigerian drug trial |journal=BMJ |date=16 August 2011 |volume=343 |issue=aug16 3 |pages=d5268 |doi=10.1136/bmj.d5268 |pmid=21846712 |s2cid=8758603}}</ref>\n\n===Inflating Prices===\nIn July 2022, UK antitrust authorities fined Pfizer \u00a363 million for unfairly high priced drug that aids in controlling epileptic seizures. The Competition and Markets Authority stated that the company took advantage of loopholes by de-branding epilepsy drug Epanutin, by doing so the price of Epanutin's price was not regulated to the same standards the company are used to and therefore the price of the drug was raised. It was stated that over a four-year period, Pfizer had billed Epanutin for around 780% and 1,600% higher than its standard price.<ref>{{cite web |url=https://www.bloomberg.com/news/articles/2022-07-21/pfizer-flynn-fined-70-million-for-unfair-epilepsy-drug-prices#xj4y7vzkg|title=Pfizer, Flynn Fined \u00a370 Million for Epilepsy Drug Prices|last=Browning|first=Jonny|date=21 July 2022|website=bloomberg.com|publisher=Bloomberg|access-date=27 July 2022}}</ref>\n\n===Allegations of patent infringement on mRNA technology===\n\nIn August 2022, [[Moderna]] announced that it will sue Pfizer and its partner [[BioNTech]] for [[Patent infringement|infringing their patent]] on the mRNA technology.<ref>{{cite news |last1=Reed |first1=Jim |title=Moderna suing Pfizer over Covid vaccine technology |url=https://www.bbc.com/news/health-62691102 |access-date=2022-08-27 |work=[[BBC News]] |date=2022-08-26}}</ref>\n\n==Environmental record==\nSince 2000, the company has implemented more than 4,000 [[greenhouse gas]] reduction projects.<ref>{{Cite news |url=https://www.uschamber.com/article/pfizer-implemented-more-4000-greenhouse-gas-reduction-projects-2000 |title=Pfizer Implemented More than 4,000 Greenhouse Gas Reduction Projects Since 2000 |work=[[United States Chamber of Commerce]] |date=November 15, 2019}}</ref>\n\nIn 2012, the company was named to the [[Carbon Disclosure Project]]'s Carbon Leadership Index in recognition of its efforts to reduce [[greenhouse gas emissions]].<ref>{{Cite press release |title=Pfizer Recognized by Carbon Disclosure Project for Carbon Performance |url=https://www.businesswire.com/news/home/20120913006098/en/Pfizer-Recognized-Carbon-Disclosure-Project-Carbon-Performance |publisher=Pfizer |via=[[Business Wire]] |date=September 13, 2012}}</ref>\n\nPfizer has inherited Wyeth's liabilities in the [[American Cyanamid]] site in [[Bridgewater Township, New Jersey]], a highly toxic EPA [[Superfund]] site. Pfizer has since attempted to remediate this land in order to clean and develop it for future profits and potential public uses.<ref>{{Cite web |title=American Cyanamid Superfund Site Fact Sheet |url=https://www.nj.gov/dep/srp/community/sites/pi/american_cyanamid_fs.pdf |website=[[New Jersey]] |date=December 2011}}</ref> The [[Sierra Club]] and the [[Edison Wetlands Association]] have opposed the cleanup plan, arguing that the area is subject to flooding, which could cause pollutants to leach. The EPA considers the plan the most reasonable from considerations of safety and cost-effectiveness, arguing that an alternative plan involving trucking [[contaminated soil]] off site could expose cleanup workers. The EPA's position is backed by the environmental watchdog group CRISIS.<ref>{{Cite news |title=Activists say EPA $204M fix for polluted American Cyanamid property will not permanently resolve problem |url=https://www.nj.com/news/2012/03/activisits_say_epa_fix_for_pol.html |first=Eugene |last=Paik |work=[[NJ.com]] |date=March 9, 2012}}</ref>\n\nIn June 2002, a chemical explosion at the Groton plant injured 7 people and caused the evacuation of more than 100 homes in the surrounding area.<ref>{{cite news |url=https://www.washingtonpost.com/wp-dyn/content/article/2006/05/23/AR2006052301305_pf.html |title=The tempest |newspaper=[[The Washington Post]] |date=May 28, 2006}}</ref>\n\n==Public-private engagement==\nPfizer engages with the public and private sectors in a variety of settings including to promote [[research and development]], academic funding, event sponsorship, [[philanthropy]], and [[political lobbying]].\n\n=== Academia ===\n\n* [[Institute for Advanced Study]] - Matching gifts and direct donor.<ref>{{Cite web |last1=Simonyi |first1=Charles |last2=Dijkgraaf |first2=Robbert |date=2018 |title=Report for the Academic Year 2017-2018 |url=https://www.ias.edu/sites/default/files/documents/publications/Annual%20Report%2017%E2%80%9318%20web.pdf |url-status=live |archive-url=https://web.archive.org/web/20220531231144/https://www.ias.edu/sites/default/files/documents/publications/Annual%20Report%2017%E2%80%9318%20web.pdf |archive-date=2022-05-31 |access-date=2022-08-02 |website=[[Institute for Advanced Study]]}}</ref><ref>{{Cite web |last1=Simonyi |first1=Charles |last2=Dijkgraaf |first2=Robbert |date=2014 |title=Report for the Academic Year 2013-2014 |url=https://www.ias.edu/sites/default/files/documents/publications/annualreport1314_0.pdf |url-status=live |archive-url=https://web.archive.org/web/20220802190342/https://www.ias.edu/sites/default/files/documents/publications/annualreport1314_0.pdf |archive-date=2022-08-02 |access-date=2022-08-02 |website=[[Institute for Advanced Study]]}}</ref>\n* [[University of Toronto]] - Donor to the Boundless Campaign,<ref>{{Cite web |title=Donor Listing |url=https://boundless.utoronto.ca/our-supporters/donor-listing/ |url-status=live |archive-url=https://web.archive.org/web/20220530223142/https://boundless.utoronto.ca/our-supporters/donor-listing/ |archive-date=2022-05-30 |access-date=2022-07-01 |website=[[University of Toronto]] |language=en}}</ref> and member of the President's Circle.<ref>{{Cite web |date=2022-05-01 |title=Presidents' Circle Member Listing {{!}} Ways to Give |url=https://engage.utoronto.ca/site/SPageServer?pagename=presidents_circle_member_listing |url-status=live |archive-url=https://web.archive.org/web/20220516225544/https://engage.utoronto.ca/site/SPageServer?pagename=presidents_circle_member_listing |archive-date=2022-05-16 |access-date=2022-07-01 |website=[[University of Toronto]]}}</ref>\n* [[University of Washington]] - Member of the Honor Roll of Donors, having contributed between $10 million and $50 million to funding the school as of 2020.<ref>{{Cite web |date=October 2020 |title=Honor Roll of Donors |url=https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf |url-status=live |archive-url=https://web.archive.org/web/20220610164520/https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf |archive-date=2022-06-10 |access-date=2022-06-10 |website=[[University of Washington]]; [[Amazon Web Services]]}}</ref>\n\n=== Activism ===\n* [[Habitat for Humanity]] - Donor.<ref>{{Cite web |last1=Hewitt |first1=Bradford L. |last2=Reckford |first2=Jonathan T.M. |date=2021-11-15 |title=Annual Report FY2021 |url=https://www.habitat.org/media/7101/download |url-status=live |archive-url=https://web.archive.org/web/20220721071822/https://www.habitat.org/media/7101/download |archive-date=2022-07-21 |access-date=2022-07-21 |website=[[Habitat for Humanity]]}}</ref>\n* [[Human Rights Campaign]] (HRC) - Corporate partner.<ref>{{Cite web |date= |title=Corporate Partners |url=https://www.hrc.org/about/corporate-partners |url-status=live |archive-url=https://web.archive.org/web/20220714072833/https://www.hrc.org/about/corporate-partners |archive-date=2022-07-14 |access-date=2022-07-14 |website=[[Human Rights Campaign]]}}</ref> HRC is a large [[LGBT]] civil rights activism group.\n* [[National Women's Law Center]] - Donor.<ref>{{Cite web |date=2016 |title=Annual Report FY 2015-2016 |url=https://nwlc.org/wp-content/uploads/2021/11/final_FY2015-2016_NWLC_AnnualReport.pdf |url-status=live |archive-url=https://web.archive.org/web/20220420023726/https://nwlc.org/wp-content/uploads/2021/11/final_FY2015-2016_NWLC_AnnualReport.pdf |archive-date=2022-04-20 |access-date=2022-07-04 |website=[[National Women's Law Center]]}}</ref>\n* [[Share Our Strength]] - Donor.<ref>{{Cite web |last1=Shore |first1=Billy |last2=Nelson |first2=Tom |date=2017 |title=No Kid Hungry 2017 |url=https://www.shareourstrength.org/wp-content/uploads/2018/05/AnnualReport_2017_mid.pdf |url-status=live |access-date=2022-07-03 |website=Share Our Strength}}</ref>\n* [[WaterAid]] - Partner.<ref>{{Cite web |date=2011 |title=Investments in Health - Pfizer 2010 Annual Review |url=https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2010/access-investments.html |url-status=live |archive-url=https://web.archive.org/web/20220812064428/https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2010/access-investments.html |archive-date=2022-08-12 |access-date=2022-08-12 }}</ref>\n\n=== Conferences and summits ===\n\n* Women in Medicine Summit - Sponsor.<ref>{{Cite web |title=Sponsors - Past Sponsors |url=https://www.womeninmedicinesummit.org/sponsors-past-sponsors |access-date=2022-05-07 |website=Women in Medicine |language=en-US}}</ref>\n* World Neuroscience Innovation Forum - Strategic partner.<ref>{{Cite web |title=Sponsors |url=https://neuroscienceinnovationforum.org/sponsors/ |url-status=live |archive-url=https://archive.today/20220615052144/https://neuroscienceinnovationforum.org/sponsors/ |archive-date=June 15, 2022 |access-date=2022-06-15 |website=World Neuroscience Innovation Forum |language=en-US }}</ref>\n\n=== Media ===\nDuring the [[COVID-19 pandemic]], Pfizer engaged many forms of media to promote their [[Pfizer COVID-19 vaccine|COVID-19 vaccine]], including a commissioned [[National Geographic]] documentary.<ref>{{Cite web |last=Snyder Bulik |first=Beth |date=2021-02-24 |title='Mission Possible': Pfizer and BioNTech star in their own vaccine discovery movie |url=https://www.fiercepharma.com/marketing/mission-possible-pfizer-and-biontech-star-vaccine-discovery-movie |url-status=live |archive-url=https://archive.today/20220408053736/https://www.fiercepharma.com/marketing/mission-possible-pfizer-and-biontech-star-vaccine-discovery-movie |archive-date=April 8, 2022 |access-date=2022-04-08 |website=Fierce Pharma |language=en }}</ref> Pfizer is also a donor to the [[National Geographic Society]].<ref>{{Cite web |date=2016 |title=The Power of Philanthropy |url=https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf |url-status=live |archive-url=https://web.archive.org/web/20220510054615/https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf |archive-date=2022-05-10 |access-date=2022-05-10 |website=National Geographic}}</ref>\n\nPfizer was a prominent sponsor of the [[Oscars 2022|2022 Oscars ceremony]] alongside [[BioNTech]].<ref>{{Cite web |last=Adams |first=Ben |date=2022-03-28 |title=Pfizer and BioNTech go to Hollywood with splashy Oscars sponsorship |url=https://www.fiercepharma.com/marketing/pfizer-and-biontech-take-hollywood-they-sponsor-oscars |url-status=live |archive-url=https://archive.today/20220330175317/https://www.fiercepharma.com/pharma/lipocine-antares-score-fda-nod-trt-tlando-oral-treatment-hypogonadism |archive-date=March 30, 2022 |access-date=2022-05-23 |website=[[Fierce Pharma]] |language=en }}</ref>\n\nPfizer has been a major donor to the [[National Press Foundation]].<ref>{{Cite web |date=2013 |title=National Press Foundation |url=http://nationalpress.org/about/our-funders/ |url-status=dead |archive-url=https://web.archive.org/web/20130128213106/http://nationalpress.org/about/our-funders/ |archive-date=2013-01-28 |access-date=2022-05-24 |website=[[National Press Foundation]]}}</ref><ref>{{Cite web |date=2010 |title=Our Funders |url=http://nationalpress.org/about/our-funders/ |url-status=dead |archive-url=https://web.archive.org/web/20100926162431/http://nationalpress.org/about/our-funders/ |archive-date=2010-09-26 |access-date=2022-05-24 |website=[[National Press Foundation]]}}</ref> Pfizer sponsored a program for the NPF called \"Cancer Issues 2010\" to train journalists to \"understand the latest research\" on various cancers, including the role of pharmaceutical products and vaccines. [[MicroRNA]] (miRNA) was also a listed topic.<ref>{{Cite web |date=2010 |title=Cancer Issues 2010 |url=http://nationalpress.org/programs-and-resources/program/cancer-issues-2010/ |url-status=dead |archive-url=https://web.archive.org/web/20100830005040/http://nationalpress.org/programs-and-resources/program/cancer-issues-2010/ |archive-date=2010-08-30 |access-date=2022-05-24 |website=National Press Foundation}}</ref><ref>{{Cite web |last=Raeburn |first=Paul |date=2010-10-13 |title=Cover this great cancer conference! (Yes, there's a catch...) |url=https://ksj.mit.edu/tracker-archive/cover-great-cancer-conference-yes-theres/ |url-status=live |archive-url=https://web.archive.org/web/20220524144432/http://ksj.mit.edu/tracker-archive/cover-great-cancer-conference-yes-theres/ |archive-date=2022-05-24 |access-date=2022-05-24 |website=[[Knight Science Journalism]] @MIT |language=en-US}}</ref>\n\nPfizer sponsors [[19 to Zero]], a \"coalition of academics, public health experts, behavioural economists, and creative professionals\" that develops media and educational materials to influence public perception surrounding [[COVID-19]] and [[COVID-19 vaccine]]s.<ref>{{Cite web |date=2021-06-03 |title=Who We Are |url=https://www.19tozero.ca/who-we-are |url-status=dead |archive-url=https://web.archive.org/web/20220719223946/https://www.19tozero.ca/who-we-are |archive-date=July 19, 2022 |access-date=2022-06-19 |website=19 to Zero}}</ref>\n\n=== Medical societies ===\n\n* [[American Society of Hematology]] - Sponsor.<ref>{{Cite web |title=Corporate Support |url=https://www.hematology.org/about/corporate-support |url-status=live |archive-url=https://archive.today/20220610180740/https://www.hematology.org/about/corporate-support |archive-date=June 10, 2022 |access-date=2022-06-10 |website=[[American Society of Hematology]] |language=en }}</ref>\n* Arthritis Society - National partner. Pfizer also supports the organization's provincial branches in [[Alberta]], [[British Columbia]], [[Manitoba]], [[New Brunswick]], [[Newfoundland and Labrador]], [[Nova Scotia]], [[Ontario]], [[Prince Edward Island]], and [[Quebec]].<ref>{{Cite web |title=Partners |url=https://arthritis.ca/about-us/partners |url-status=live |archive-url=https://archive.today/20220514211808/https://arthritis.ca/about-us/partners |archive-date=May 14, 2022 |access-date=2022-05-14 |website=The Arthritis Society }}</ref>\n* [[Canadian Cancer Society]] - Sponsor.<ref>{{Cite web |title=Our Corporate Partners |url=https://cancer.ca/en/get-involved/partnerships/our-corporate-partners |url-status=live |archive-url=https://archive.today/20220502135839/https://cancer.ca/en/get-involved/partnerships/our-corporate-partners |archive-date=May 2, 2022 |access-date=2022-05-15 |website=[[Canadian Cancer Society]] }}</ref>\n* [[Canadian Paediatric Society]] - Funding. CPS is the organization that administers the Canadian Immunization Monitoring Program, Active (IMPACT) vaccine safety program.<ref name=\":2\">{{Cite web |last=Public Health Agency of Canada |date=2022-02-25 |title=National Advisory Committee on Immunization (NACI): Membership and representation |url=https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html |url-status=live |archive-url=https://web.archive.org/web/20220323061520/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf |archive-date=2022-03-23 |access-date=2022-03-29 |website=Government of Canada}}</ref>\n* Canadian Society of Internal Medicine - Annual conference sponsor with [[Bristol Myers Squibb]].<ref>{{Cite web |title=Sponsors |url=https://csim.ca/conferences/virtual-annual-meeting-2021/sponsors/ |url-status=live |archive-url=https://archive.today/20220515012338/https://csim.ca/conferences/virtual-annual-meeting-2021/sponsors/ |archive-date=May 15, 2022 |access-date=2022-05-15 |website=Canadian Society of Internal Medicine |language=en-US }}</ref>\n* [[Endocrine Society]] - Corporate Liaison Board member.<ref>{{Cite web |title=Corporate Liaison Board |url=https://www.endocrine.org/membership/corporate-liaison-board |url-status=live |archive-url=https://archive.today/20220610234024/https://www.endocrine.org/membership/corporate-liaison-board |archive-date=June 10, 2022 |access-date=2022-06-10 |website=[[Endocrine Society]] |language=en }}</ref>\n* [[European Society of Cardiology]] - Sponsor of the EURObservational Research Programme.<ref>{{Cite web |title=Why sponsor the EURObservational Registry Programme |url=https://www.escardio.org/Research/Registries-%26-surveys/Sponsorship%2C%20https%3A//www.escardio.org/Research/Registries-%26-surveys/Sponsorship |url-status=live |archive-url=https://archive.today/20220615200912/https://www.escardio.org/Research/Registries-&-surveys/Sponsorship |archive-date=June 15, 2022 |access-date=2022-06-15 |website=[[European Society of Cardiology]] }}</ref>\n* Spanish Cardiac Society - Strategic partner.<ref>{{Cite web |title=Sociedad Espa\u00f1ola de Cardiolog\u00eda: profesionales sanitarios y cardi\u00f3logos |url=https://secardiologia.es/ |url-status=live |archive-url=https://web.archive.org/web/20220613161701/https://secardiologia.es/ |archive-date=2022-06-13 |access-date=2022-06-14 |website=Sociedad Espa\u00f1ola de Cardiolog\u00eda}}</ref>\n\n=== Political lobbying ===\nPfizer is affiliated with a variety of industry organizations engaging in [[lobbying in the United States|political lobbying]], and has made substantial direct donations to government and regulatory agencies:\n\n* Adult Vaccine Access Coalition - Member.<ref>{{Cite web |last= |first= |date=2021 |title=AVAC Member Organizations |url=https://adultvaccinesnow.org/our-membership/avac-member-organizations/ |url-status=live |archive-url=https://web.archive.org/web/20220708060337/https://adultvaccinesnow.org/our-membership/avac-member-organizations/ |archive-date=2022-07-08 |access-date=2022-07-08 |website=Adult Vaccine Access Coalition |language=en-US}}</ref>\n* Alliance for a Stronger FDA - Member.<ref>{{Cite web |date=2022-03-04 |title=List of Members |url=https://www.strengthenfda.org/members |url-status=live |archive-url=https://web.archive.org/web/20220708045631/https://www.strengthenfda.org/members |archive-date=2022-07-08 |access-date=2022-07-08 |website=Alliance for a Stronger FDA |language=en-US}}</ref>\n* AMR Industry Alliance - Member.<ref>{{Cite web |last= |date=2017 |title=Our Members |url=https://www.amrindustryalliance.org/our-members/ |url-status=live |archive-url=https://web.archive.org/web/20220331155516/https://www.amrindustryalliance.org/our-members/ |archive-date=2022-03-31 |access-date=2022-07-10 |website=[[AMR Industry Alliance]] |language=en-US}}</ref>\n* [[BIOTECanada]] - Member company.<ref>{{Cite web |date=2021-12-23 |title=Member Listings |url=https://www.biotech.ca/about/member-listings/ |url-status=live |archive-url=https://web.archive.org/web/20220502074149/https://www.biotech.ca/about/member-listings/ |archive-date=2022-05-02 |access-date=2022-06-18 |website=[[BIOTECanada]] |language=en-US}}</ref><ref>{{Cite web |last=Wilson |first=Barry |date=2000-10-05 |title=Biotech lobby group at heart of ethics complaint |url=https://www.producer.com/news/biotech-lobby-group-at-heart-of-ethics-complaint/ |url-status=live |archive-url=https://archive.today/20220618172657/https://www.producer.com/news/biotech-lobby-group-at-heart-of-ethics-complaint/ |archive-date=June 18, 2022 |access-date=2022-06-18 |website=[[The Western Producer]] |language=en }}</ref>\n* [[Bipartisan Policy Center]] - Donor.<ref>{{Cite web |date=2021 |title=2020-2021 Annual Report |url=https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2021/06/BPC-Annual-Report_6.8.pdf |url-status=live |archive-url=https://web.archive.org/web/20220514184516/https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2021/06/BPC-Annual-Report_6.8.pdf |archive-date=2022-05-14 |access-date=2022-07-06 |website=[[Bipartisan Policy Center]]}}</ref>\n* [[The Business Council]] - Member, represented by CEO [[Albert Bourla]].<ref>{{Cite web |date=2022 |title=Active Members |url=https://businesscouncil.com/active-members/ |url-status=live |archive-url=https://web.archive.org/web/20220713065022/https://businesscouncil.com/active-members/ |archive-date=2022-07-13 |access-date=2022-07-13 |website=[[The Business Council]]}}</ref>\n* [[United Nations Foundation|Business Council for the United Nations]] - Member.<ref>{{Cite web |title=Members |url=https://www.businesscouncilfortheun.org/bcun-members |url-status=live |archive-url=https://archive.ph/1KWMg |archive-date=2022-05-17 |access-date=2022-08-18 |website=Business Council for the United Nations |language=en-US}}</ref>\n* [[Center on Budget and Policy Priorities]] - Funder.<ref>{{Cite web |date=2013 |title=2013 Foundation and Institutional Support |url=https://www.cbpp.org/sites/default/files/atoms/files/foundationlist2013final.pdf |url-status=live |archive-url=https://web.archive.org/web/20220617124921/https://www.cbpp.org/sites/default/files/atoms/files/foundationlist2013final.pdf |archive-date=2022-06-17 |access-date=2022-07-03 |website=[[Center on Budget and Policy Priorities]]}}</ref>\n* Community Anti-Drug Coalitions of America (CADCA) - Partner.<ref>{{Cite web |last=Dean |first=Arthur T. |date=2015 |title=2015 Annual Report |url=http://2015.cadcaannualreport.org/CADCA-2015-AnnualReport.pdf |url-status=live |archive-url=https://web.archive.org/web/20220721010130/http://2015.cadcaannualreport.org/CADCA-2015-AnnualReport.pdf |archive-date=2022-07-21 |access-date=2022-07-21 |website=Community Anti-Drug Coalitions of America}}</ref>\n* COVID-19 Vaccine Education and Equity Project - Sponsor.<ref>{{Cite web |last= |date=2020 |title=About The Project |url=https://covidvaccineproject.org/about-the-project/ |url-status=live |archive-url=https://archive.ph/R2ViG |archive-date=2022-07-07 |access-date=2022-07-07 |website=COVID-19 Vaccine Education and Equity Project |language=en-US}}</ref>\n* [[European Federation of Pharmaceutical Industries and Associations]] - Member.<ref>{{Cite web |date=2022 |title=Membership |url=https://www.efpia.eu/about-us/membership/ |url-status=live |archive-url=https://web.archive.org/web/20220701031757/https://www.efpia.eu/about-us/membership/ |archive-date=2022-07-01 |access-date=2022-07-11 |website=EFPIA}}</ref>\n* [[Foundation for the National Institutes of Health]] (FNIH) - Donor. Pfizer has given between $5,000,000 and $9,999,999 to the between 1997 and 2020, contributing to funding the activities of the [[National Institutes of Health]].<ref>{{Cite web |title=2020 Donors |url=https://2020-annual-report.fnih.org/donors/ |url-status=live |archive-url=https://web.archive.org/web/20220402180716/https://2020-annual-report.fnih.org/donors/ |archive-date=2022-04-02 |access-date=2022-04-06 |website=FNIH 2020 Annual Report |language=en}}</ref>\n* [[Global Health Council]] - Member.<ref>{{Cite web |title=Members |url=https://globalhealth.org/about-us/members/ |url-status=live |archive-url=https://web.archive.org/web/20220726224915/https://globalhealth.org/about-us/members/ |archive-date=2022-07-26 |access-date=2022-07-26 |website=[[Global Health Council]] |language=en-US}}</ref>\n* Immunisation Coalition (Australia) - Sponsor.<ref>{{Cite web |title=About Us |url=https://www.immunisationcoalition.org.au/about-us/ |url-status=live |archive-url=https://web.archive.org/web/20210303185121/https://www.immunisationcoalition.org.au/about-us/ |archive-date=2021-03-03 |access-date=2022-07-01 |website=Immunisation Coalition |language=en-AU}}</ref>\n* [[Innovative Medicines Canada]] - Member. IMC is an association of pharmaceutical companies doing business in Canada.<ref>{{Cite web |title=Member Companies |url=http://innovativemedicines.ca/about/member-companies/ |url-status=live |archive-url=https://archive.today/20211103040804/http://innovativemedicines.ca/about/member-companies/ |archive-date=November 3, 2021 |access-date=2022-03-08 |website=Innovative Medicines Canada |language=en }}</ref><ref>{{Cite news |last=Grant |first=Kelly |date=2019-12-11 |title=Innovative Medicines Canada bans members from paying doctors fees for IV infusions |language=en-CA |work=The Globe and Mail |url=https://www.theglobeandmail.com/canada/article-innovative-medicines-canada-bans-members-from-paying-doctors-fees-for/ |access-date=2022-04-08}}</ref> The group lobbies the [[Government of Ontario]] and [[House of Commons of Canada]] through Rubicon Strategy, a firm owned by [[Progressive Conservative Party of Ontario]] campaign manager [[Kory Teneycke]].<ref>{{Cite web |date=2021-09-22 |title=Consultant Lobbyist Registration No. CL4899-20200917025456 |url=https://lobbyist.oico.on.ca/Pages/Public/PublicSearch/ |url-status=live |archive-url=https://ia601407.us.archive.org/2/items/consultant_lobbyist_registration_no._CL4899-20200917025456/screencapture-lobbyist-oico-on-ca-Pages-Public-PublicSearch-ConsultantLobbyistPreview-aspx-2022-03-08-09_54_13.pdf |archive-date=2022-03-08 |access-date=2022-03-08 |website=Office of the Integrity Commissioner of Ontario}}</ref><ref>{{Cite web |last=Maher |first=Stephen |date=2019-01-29 |title=For access to the Ford government, two names matter most |url=https://www.macleans.ca/politics/for-access-to-the-ford-government-two-names-matter-most/ |url-status=live |archive-url=https://archive.today/20210322062629/https://www.macleans.ca/politics/for-access-to-the-ford-government-two-names-matter-most/ |archive-date=March 22, 2021 |access-date=2022-03-08 |website=MacLean's }}</ref><ref>{{Cite web |last= |first= |date=2022-03-28 |title=Innovative Medicines Canada/M\u00e9dicaments Novateurs Canada / Andrew Balfour, Consultant |url=https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/clntSmmry?clientOrgCorpNumber=367878&sMdKy=1621857998861 |url-status=live |archive-url=https://archive.today/20220408060852/https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/clntSmmry?clientOrgCorpNumber=367878&sMdKy=1621857998861 |archive-date=April 8, 2022 |access-date=2022-04-08 |website=Registry of Lobbyists }}</ref>\n* [[International Federation of Pharmaceutical Manufacturers & Associations]] (IFPMA) - Member.<ref>{{Cite web |title=Companies |url=https://www.ifpma.org/who-we-are/our-membership/full-members/companies/ |url-status=live |archive-url=https://web.archive.org/web/20220701150736/https://www.ifpma.org/who-we-are/our-membership/full-members/companies/#!/ |archive-date=2022-07-01 |access-date=2022-07-01 |website=[[International Federation of Pharmaceutical Manufacturers and Associations]] |language=en-GB}}</ref>\n* Life Sciences British Columbia (LSBC) - Member company and Platinum Sponsor.<ref>{{Cite web |last= |date=2007-10-18 |title=LifeSciences British Columbia Pfizer Announcement |url=https://vitp.ca/post417/ |url-status=live |archive-url=https://archive.today/20220425070435/https://vitp.ca/post417/ |archive-date=April 25, 2022 |access-date=2022-04-25 |website=Vancouver Island Technology Park (VITP) }}</ref><ref>{{Cite web |title=Our Sponsors |url=https://lifesciencesbc.ca/membership/our-sponsors/ |url-status=live |archive-url=https://archive.today/20220425063149/https://lifesciencesbc.ca/membership/our-sponsors/ |archive-date=April 25, 2022 |access-date=2022-04-25 |website=Life Sciences British Columbia |date=January 6, 2021 |language=en-US }}</ref>\n* [[National Health Council]] (NHC) - Member organization. NHC is a non-profit organization that lobbies the [[U.S. Government]] on issues related to [[Healthcare reform in the United States|healthcare reform]].<ref>{{Cite web |title=Our Members |url=https://nationalhealthcouncil.org/members/ |url-status=live |archive-url=https://web.archive.org/web/20220406081753/https://nationalhealthcouncil.org/members/?m_cat=74&m_key= |archive-date=2022-04-06 |access-date=2022-04-06 |website=National Health Council |language=en-US}}</ref>\n* National Pharmaceutical Council (NPC) - Member company.<ref>{{Cite web |title=Members |url=https://www.npcnow.org/about/members |url-status=live |archive-url=https://archive.today/20220407004632/https://www.npcnow.org/about/members |archive-date=April 7, 2022 |access-date=2022-04-07 |website=National Pharmaceutical Council |language=en }}</ref>\n* Personalized Medicine Coalition (PMC) - Member.<ref>{{Cite web |title=Current Members |url=https://www.personalizedmedicinecoalition.org/Members/Current_Members |url-status=live |archive-url=https://web.archive.org/web/20210815032705/https://personalizedmedicinecoalition.org/Members/Current_Members |archive-date=2021-08-15 |access-date=2022-04-06 |website=Personalized Medicine Coalition |language=en}}</ref><ref>{{Cite web |date=2021-04-01 |title=SHOWCASE: Precision Medicine: Expanding the Frontiers of Precision Medicine |url=https://www.pharmavoice.com/news/2021-04-precision-medicine/612084/ |url-status=live |archive-url=https://web.archive.org/web/20220408054844/https://www.pharmavoice.com/news/2021-04-precision-medicine/612084/ |archive-date=2022-04-08 |access-date=2022-04-08 |website=PharmaVoice |language=en-US}}</ref>\n* [[Pharmaceutical Advertising Advisory Board]] (PAAB) - Client.<ref>{{Cite web |last= |first= |title=Our Organization |url=https://www.paab.ca/about.htm |url-status=live |archive-url=https://web.archive.org/web/20220425051012/https://www.paab.ca/about.htm |archive-date=2022-04-25 |access-date=2022-04-25 |website=Pharmaceutical Advertising Advisory Board |language=en}}</ref>\n* [[Pharmaceutical Research and Manufacturers of America]] (PhRMA) - Member company.<ref>{{Cite web |title=About |url=https://www.phrma.org/about |url-status=live |archive-url=https://archive.today/20220406052447/https://www.phrma.org/about |archive-date=April 6, 2022 |access-date=2022-04-06 |website=PhRMA }}</ref><ref>{{Cite web |last=Schwartz |first=Brian |date=2021-06-01 |title=Big Pharma lobbyists launch campaign against Biden over Covid vaccine patent waiver |url=https://www.cnbc.com/2021/06/01/big-pharma-launches-campaign-against-biden-over-covid-vaccine-patent-waiver.html |url-status=live |archive-url=https://archive.today/20210602022055/https://www.cnbc.com/2021/06/01/big-pharma-launches-campaign-against-biden-over-covid-vaccine-patent-waiver.html |archive-date=June 2, 2021 |access-date=2022-04-08 |website=CNBC |language=en }}</ref>\n* [[Reagan-Udall Foundation|Reagan-Udall Foundation for the Food and Drug Administration]] - Donor.<ref>{{Cite web |date=2021 |title=2021 Annual Report |url=https://reaganudall.org/about-us/annual-reports/2021-annual-report |url-status=live |archive-url=https://web.archive.org/web/20220712045554/https://reaganudall.org/about-us/annual-reports/2021-annual-report |archive-date=2022-07-12 |access-date=2022-07-12 |website=[[Reagan-Udall Foundation]]}}</ref>\n* Research!America - Member organization.<ref>{{Cite web |date=2007-09-28 |title=Member Organizations |url=https://www.researchamerica.org/about-us/member-organizations |url-status=live |archive-url=https://archive.today/20220406092643/https://www.researchamerica.org/about-us/member-organizations |archive-date=April 6, 2022 |access-date=2022-04-06 |website=Research!America |language=en }}</ref>\n* [[U.S. Global Leadership Coalition]] - Member.<ref>{{Cite web |url=https://www.usglc.org/about-us/coalition-members/ |title=U.S. Global Leadership Coalition, Global Trust members |publisher=[[U.S. Global Leadership Coalition]]}}</ref>\n* [[World Economic Forum]] - Member organization.<ref>{{Cite web |last=Ivan |first=Wecke |date=2021-08-16 |title=Conspiracy theories aside, there is something fishy about the Great Reset |url=https://www.opendemocracy.net/en/oureconomy/conspiracy-theories-aside-there-something-fishy-about-great-reset/ |url-status=live |archive-url=https://archive.today/20220404023305/https://www.opendemocracy.net/en/oureconomy/conspiracy-theories-aside-there-something-fishy-about-great-reset/ |archive-date=April 4, 2022 |access-date=2022-04-08 |website=openDemocracy |language=en }}</ref><ref>{{Cite web |title=Pfizer |url=https://www.weforum.org/organizations/pfizer/ |url-status=live |archive-url=https://archive.today/20220314092916/https://www.weforum.org/organizations/pfizer |archive-date=March 14, 2022 |access-date=2022-04-06 |website=World Economic Forum |language=en }}</ref>\n\n[[Scott Gottlieb]], who resigned as [[FDA commissioner]] in April 2019, joined the Pfizer [[board of directors]] three months later, in July 2019.<ref>{{Cite news |last=Mishra |first=Manas |date=July 2, 2019 |title=Senator Warren asks former FDA chief Gottlieb to resign from Pfizer board |work=[[Reuters]] |editor-last=Kuber |editor-first=Shailesh |url=https://www.reuters.com/article/us-pfizer-board-scott-gottlieb/senator-warren-asks-former-fda-chief-gottlieb-to-resign-from-pfizer-board-idUSKCN1TX2IX}}</ref>\n\nPfizer lobbied various officials in the [[Government of British Columbia]] between April and November 2012, including then-premier [[Christy Clark]], future premier [[John Horgan]], future health minister [[Adrian Dix]], and future deputy premier, minister of public safety and solicitor general [[Mike Farnworth]]. The disclosed purpose was to \"provide health policy and pharmaceutical information and communications on behalf of Pfizer Canada,\" and \"learn and understand the budgetary, policy and strategic directions of the Government.\"<ref>{{Cite web |last= |first= |date=2012-04-10 |title=Registration ID: 200777 |url=https://www.lobbyistsregistrar.bc.ca/app/secure/orl/lrs/do/vwRg?cno=2406&regId=200777 |url-status=live |archive-url=https://archive.today/20220426232441/https://www.lobbyistsregistrar.bc.ca/app/secure/orl/lrs/do/vwRg?cno=2406&regId=200777 |archive-date=April 26, 2022 |access-date=2022-04-26 |website=BC Office of the Registrar of Lobbyists |language=en }}</ref>\n\n=== Professional associations ===\n\n* Bioscience Association Manitoba (BAM) - Sponsor.<ref>{{Cite web |date=2021 |title=Sponsors |url=https://www.biomb.ca/members/sponsors |url-status=live |archive-url=https://web.archive.org/web/20210923022753/https://www.biomb.ca/members/sponsors |archive-date=2021-09-23 |access-date=2022-07-01 |website=[[Bioscience Association Manitoba]] |language=en-ca}}</ref>\n* British Columbia Pharmacy Association (BCPA) - Event sponsor.<ref>{{Cite web |title=Our Sponsors and Prizes |url=https://www.bcpharmacy.ca/conference/prizes/2022 |url-status=live |archive-url=https://archive.today/20220523043337/https://www.bcpharmacy.ca/conference/prizes/2022 |archive-date=May 23, 2022 |access-date=2022-05-23 |website=BC Pharmacy Association }}</ref>\n* Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) - Patron (former).<ref>{{Cite web |date=2010-07-14 |title=Patrons |url=https://www.cacmid.ca/ |url-status=dead |archive-url=https://web.archive.org/web/20150909030457/http://www.cacmid.ca/cacmid/patrons/ |archive-date=2015-09-09 |access-date=2022-07-01 |website=CACMID}}</ref>\n* [[Canadian Association of Emergency Physicians]] (CAEP) - Corporate partner.<ref>{{Cite web |date=2019 |title=Annual Report 2018-2019 |url=https://caep.ca/wp-content/uploads/2019/06/Annual-Report2019-V2.pdf |url-status=live |archive-url=https://web.archive.org/web/20220420013556/https://caep.ca/wp-content/uploads/2019/06/Annual-Report2019-V2.pdf |archive-date=2022-04-20 |access-date=2022-06-18 |website=[[Canadian Association of Emergency Physicians]]}}</ref>\n* Canadian Association of Medical Oncologists - Annual meeting sponsor.<ref>{{Cite web |title=Pfizer Sponsor Showcase |url=https://camo-acom.ca/Pfizer-Sponsor-Showcase |url-status=live |archive-url=https://archive.today/20220523181824/https://camo-acom.ca/Pfizer-Sponsor-Showcase |archive-date=May 23, 2022 |access-date=2022-05-23 |website=[[Canadian Association of Medical Oncologists]] }}</ref>\n* [[Canadian Medical Association]] - Sponsor. In 2009, Pfizer partnered with the CMA to launch a continuing medical education course for physicians.<ref>{{Cite news |last=Weeks |first=Carly |date=2009-12-02 |title=Medical association takes heat for Pfizer funding |language=en-CA |work=The Globe and Mail |url=https://www.theglobeandmail.com/life/health-and-fitness/medical-association-takes-heat-for-pfizer-funding/article568583/ |access-date=2022-06-09}}</ref>\n* [[Canadian Pharmacists Association]] and [[Canadian Pharmacists Journal]] - Sponsor.<ref>{{Cite journal |date=May 2014 |title=Meet Our Sponsors |journal=Canadian Pharmacists Journal / Revue des Pharmaciens du Canada |language=en |volume=147 |issue=3 |pages=191\u2013192 |doi=10.1177/1715163514530860 |issn=1715-1635 |pmc=4025887 |pmid=24847373 }}</ref>\n* [[Canadian Public Health Association]] - Sponsor.<ref>{{Cite web |title=2018 Annual Report |url=https://www.cpha.ca/sites/default/files/uploads/about/reports/2018-annual-report-web-e.pdf |url-status=live |archive-url=https://web.archive.org/web/20210608184141/https://www.cpha.ca/sites/default/files/uploads/about/reports/2018-annual-report-web-e.pdf |archive-date=2021-06-08 |access-date=2022-03-18 |website=Canadian Public Health Association}}</ref>\n* Canadian Rheumatology Association - Sponsor.<ref>{{Cite web |date=January 2022 |title=2020-2021 Annual Report: Collaboration, Resilience and Advancement |url=https://rheum.ca/wp-content/uploads/2022/01/CRA_20-21_AnnualReport_EN.pdf |url-status=live |archive-url=https://web.archive.org/web/20220301043916/https://rheum.ca/wp-content/uploads/2022/01/CRA_20-21_AnnualReport_EN.pdf |archive-date=2022-03-01 |access-date=2022-06-11 |website=[[Canadian Rheumatology Association]]}}</ref>\n* Canadian Urological Association - Sponsor.<ref>{{Cite web |date=2021 |title=Home |url=https://cuameeting.org/en/ |url-status=live |archive-url=https://archive.ph/iiAEA |archive-date=2022-05-16 |access-date=2022-07-01 |website=CUA 2022}}</ref><ref>{{Cite web |last=McLorie |first=Gordon |date=2000 |title=Fall 2000 Newsletter |url=http://history.cua.org/sites/default/files/2018-07/2000-02_en.pdf |url-status=live |archive-url=https://web.archive.org/web/20220701072809/http://history.cua.org/sites/default/files/2018-07/2000-02_en.pdf |archive-date=2022-07-01 |access-date=2022-07-01 |website=[[Canadian Urological Association]]}}</ref>\n* [[Ontario Medical Association]] (OMA) - Donor to the Ontario Medical Foundation.<ref>{{Cite web |date=2022 |title=Your impact |url=https://www.oma.org/what-we-do/ontario-medical-foundation/your-impact/ |url-status=live |archive-url=https://web.archive.org/web/20220609072754/https://www.oma.org/what-we-do/ontario-medical-foundation/your-impact/ |archive-date=2022-06-09 |access-date=2022-07-01 |website=[[Ontario Medical Association]]}}</ref>\n* Pharmacy Association of Nova Scotia - Sponsor.<ref>{{Cite web |title=Pfizer Canada - Platinum Sponsor |url=https://pans.ns.ca/pfizer-canada-platinum-sponsor |url-status=live |archive-url=https://archive.today/20220523075031/https://pans.ns.ca/pfizer-canada-platinum-sponsor |archive-date=May 23, 2022 |access-date=2022-05-23 |website=Pharmacy Association of Nova Scotia }}</ref>\n\n=== Public health ===\nPfizer has engaged in a number of [[public health]] and [[Global Health Initiatives|global health]] initiatives worldwide, and provides funding for health care facilities of various specialties in [[Healthcare in Canada|Canada]] and the [[Healthcare in the United States|United States]]:\n\n* CANImmunize - Endorsing partner.<ref name=\":3\" /> CANImmunize is a [[Vaccine passports during the COVID-19 pandemic|vaccine passport]] software company funded primarily by the [[Public Health Agency of Canada]], and partnered with governments, health agencies, academia and pharmaceutical companies across Canada.\n* [[Centre for Addiction and Mental Health]] - Donor.<ref>{{Cite web |date=2021 |title=Thank you to our donors |url=https://www.camh.ca/-/media/files/camhf-2020-21-annual-report-donor-listing.pdf |url-status=live |archive-url=https://web.archive.org/web/20220619084300/https://www.camh.ca/-/media/files/camhf-2020-21-annual-report-donor-listing.pdf |archive-date=2022-06-19 |access-date=2022-07-01 |website=[[Centre for Addiction and Mental Health]]}}</ref>\n* [[Dana\u2013Farber Cancer Institute]] - Donor.<ref>{{Cite web |title=2012 Honor Roll of Donors |url=https://www.pageturnpro.com/Dana-Farber-Cancer-Institute-and-The-Jimmy-Fund/49214-2012-Honor-Roll-of-Donors/sdefault.html#page/8 |url-status=live |access-date=2022-08-13 |website=[[Dana\u2013Farber Cancer Institute]]; PageTurnPro}}</ref>\n* Federation of Medical Women of Canada - Sponsor.<ref>{{Cite web |date=2009 |title=AGM, Leadership & Advocacy Workshops 09 |url=https://fmwc.ca/wp-content/uploads/2013/12/FMWC_Fall_2009_issue.pdf |url-status=live |archive-url=https://web.archive.org/web/20220306100401/https://fmwc.ca/wp-content/uploads/2013/12/FMWC_Fall_2009_issue.pdf |archive-date=2022-03-06 |access-date=2022-06-09 |website=Federation of Medical Women of Canada}}</ref><ref>{{Cite web |title=Sponsors & Partners |url=https://fmwc.ca/about-us/sponsors-partners/ |url-status=live |archive-url=https://archive.today/20220609072736/https://fmwc.ca/about-us/sponsors-partners/ |archive-date=June 9, 2022 |access-date=2022-06-09 |website=Federation of Medical Women of Canada }}</ref>\n* Food Allergy Canada - Corporate partner, providing funding and advocacy support.<ref>{{Cite web |date=2021 |title=Impact report 2020: Pivoting with the pandemic |url=https://foodallergycanada.ca/wp-content/uploads/FAC-ImpactReport-2020.pdf |url-status=live |archive-url=https://web.archive.org/web/20220418184526/https://foodallergycanada.ca/wp-content/uploads/FAC-ImpactReport-2020.pdf |archive-date=2022-04-18 |access-date=2022-04-18 |website=Food Allergy Canada}}</ref><ref>{{Cite web |title=Who we work with |url=https://foodallergycanada.ca/our-impact-advocacy-and-services/about-us/who-we-work-with/ |url-status=live |archive-url=https://archive.today/20220103024343/https://foodallergycanada.ca/our-impact-advocacy-and-services/about-us/who-we-work-with/ |archive-date=January 3, 2022 |access-date=2022-04-18 |website=Food Allergy Canada |language=en-US }}</ref>\n* [[Hospital for Sick Children (Toronto)|Hospital for Sick Children (SickKids)]] - Donor to the SickKids Foundation.<ref>{{Cite web |date=2021 |title=2020-21 SickKids Annual Report |url=https://web.sickkidsfoundation.com/annual-report-2020/ |url-status=live |archive-url=https://web.archive.org/web/20220620073404/https://web.sickkidsfoundation.com/annual-report-2020/ |archive-date=2022-06-20 |access-date=2022-07-01 |website=[[SickKids|SickKids Foundation]]}}</ref>\n* Medical Teams International - Corporate donor.<ref>{{Cite web |date=2016 |title=Partners |url=http://www.medicalteams.org/take-action/corporate-partnerships/partners/humanitarian-aid-donors |url-status=usurped |archive-url=https://web.archive.org/web/20180129121956/http://www.medicalteams.org/take-action/corporate-partnerships/partners/humanitarian-aid-donors |archive-date=2018-01-29 |access-date=2022-08-05 |website=[[Medical Teams International]]}}</ref>\n* [[North Bay Regional Health Center]] - Donor to the NBRHC Foundation.<ref>{{Cite web |date=2019 |title=Donor List |url=https://nbrhc.on.ca/wp-content/uploads/2019/12/2019-Donor-Wall-List.doc |url-status=live |archive-url=https://web.archive.org/web/20220701202805/https://nbrhc.on.ca/wp-content/uploads/2019/12/2019-Donor-Wall-List.doc |archive-date=2022-07-01 |access-date=2022-07-01 |website=[[North Bay Regional Health Center]]}}</ref>\n* [[Princess Margaret Cancer Centre]] (PMCC) - Conference sponsor,<ref>{{Cite web |title=The 8th Princess Margaret Hospital Conference: Developments in Cancer Management |url=https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html |url-status=live |archive-url=https://web.archive.org/web/20220620072213/https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html?page=1 |archive-date=2022-06-20 |access-date=2022-07-01 |website=FDocuments India |language=en}}</ref> and donor to the Princess Margaret Cancer Foundation.<ref>{{Cite web |date=2021 |title=2021 Annual Report |url=https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf |url-status=live |archive-url=https://web.archive.org/web/20211120191604/https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf |archive-date=2021-11-20 |access-date=2022-07-01 |website=Princess Margaret Cancer Foundation}}</ref>\n* [[Scarborough Health Network]] (SHN) - Donor to the SHN Foundation.<ref>{{Cite web |date=2021 |title=Our Donors |url=https://www.shnfoundation.ca/our-donors/ |url-status=live |archive-url=https://web.archive.org/web/20220620072949/https://www.shnfoundation.ca/our-donors/ |archive-date=2022-06-20 |access-date=2022-07-01 |website=[[Scarborough Health Network|Scarborough Health Network Foundation]] |language=en-CA}}</ref> \n* [[Sinai Health System|Sinai Health Foundation]] - Donor. The foundation funds [[Mount Sinai Hospital (Toronto)|Mount Sinai Hospital]], [[Bridgepoint Active Healthcare]], and the [[Lunenfeld-Tanenbaum Research Institute]] in [[Toronto]], [[Ontario]].<ref>{{Cite web |title=Donor List - 2020-2021 |url=https://www.sinaihealthannualreport.ca/donor-list-2020-2021 |url-status=live |archive-url=https://web.archive.org/web/20220516074559/https://www.sinaihealthannualreport.ca/donor-list-2020-2021 |archive-date=2022-05-16 |access-date=2022-05-16 |website=Sinai Health Annual Report}}</ref> \n* [[Sunnybrook Health Sciences Centre]] - Donor.<ref>{{Cite web |date=2022 |title=Our donors - Your Impact |url=https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html |url-status=live |archive-url=https://web.archive.org/web/20220620153915/https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html |archive-date=2022-06-20 |access-date=2022-07-01 |website=[[Sunnybrook Health Sciences Centre|Sunnybrook Foundation]] |language=en}}</ref> \n* University Hospitals Kingston Foundation - Donor.<ref>{{Cite web |date=2022 |title=Recognizing Your Contribution |url=https://www.uhkf.ca/Your-Impact/Recognizing-Your-Contribution |url-status=live |archive-url=https://web.archive.org/web/20220504073124/https://www.uhkf.ca/Your-Impact/Recognizing-Your-Contribution |archive-date=2022-05-04 |access-date=2022-07-01 |website=Kingston University Hospital Foundation |language=en-CA}}</ref> UHKF raises funds for the Kingston Health Sciences Centre and [[Providence Care]]. \n* [[William Osler Health System]] - Event sponsor.<ref>{{Cite web |title=Holi Gala Festival of Colours 2022 |url=https://support.oslerfoundation.org/site/SPageServer?pagename=holigala22_our_sponsors |url-status=live |archive-url=https://archive.today/20220617074329/https://support.oslerfoundation.org/site/SPageServer?pagename=holigala22_our_sponsors |archive-date=June 17, 2022 |access-date=2022-06-17 |website=[[William Osler Health System|William Osler Health System Foundation]] }}</ref>\nPfizer sponsored a presentation in January 2020 delivered by Julie Bettinger through [[British Columbia]]'s [[Provincial Health Services Authority]] (PHSA) titled \"Vaccine hesitancy: It doesn't matter if the vaccine works if nobody gets it.\"<ref name=\":2\" /><ref>{{Cite web |last=Bettinger |first=Julie |date=2020-01-24 |title=Vaccine Hesitancy: It doesn't matter if the vaccine works if nobody gets it |url=https://mediasite.phsa.ca/Mediasite/Catalog/Mobile/FolderPresentation/22912938f963448cab10cf3719de3d5e21/22912938f963448cab10cf3719de3d5e21/b27eb1456cb14e06af5370550b1c5e431d/ |url-status=live |archive-url=https://web.archive.org/web/20210118225408/https://mediasite.phsa.ca/Mediasite/Catalog/Mobile/FolderPresentation/22912938f963448cab10cf3719de3d5e21/22912938f963448cab10cf3719de3d5e21/b27eb1456cb14e06af5370550b1c5e431d/ |archive-date=2021-01-18 |access-date=2022-03-29 |website=Provincial Health Sciences Authority}}</ref>\n\nIn 2020, Pfizer provided funding in the range of $100,000.00 - $250,000.00 to [[Ronald McDonald House Charities]] \u201cto provide resources that directly improve the health and well-being of children and their families.\u201d<ref>{{Cite web |title=Corporate Sponsors of RMHC |url=https://rmhc.org/about-us/our-partners |url-status=live |archive-url=https://web.archive.org/web/20220512061331/https://rmhc.org/about-us/our-partners |archive-date=2022-05-12 |access-date=2022-06-08 |website=[[Ronald McDonald House Charities]] |language=en}}</ref>\n\n=== Research and development ===\nPfizer has partnered with and sponsored many medical research networks and professional associations in the United States, Canada and globally:\n\n* ABC Global Alliance - Main sponsor.<ref>{{Cite web |date=2022 |title=Our Sponsors |url=https://www.abcglobalalliance.org/who-we-are/our-supporters/ |url-status=live |archive-url=https://archive.today/20220523190512/https://www.abcglobalalliance.org/who-we-are/our-supporters/ |archive-date=May 23, 2022 |access-date=2022-05-23 |website=ABC Global Alliance |language=en-US }}</ref> The alliance is a Portuguese not-for-profit society supporting research into advanced breast cancer.\n* Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) - Industry partner.\n* [[AdvaMed]] - Member (former).<ref>{{Cite web |date=2014-07-13 |title=Members |url=http://advamed.org/page/33/members |url-status=usurped |archive-url=https://web.archive.org/web/20140713182356/http://advamed.org/page/33/members |archive-date=2014-07-13 |access-date=2022-06-13 |website=[[AdvaMed]]}}</ref>\n* Alliance for Regenerative Medicine - Member organization.<ref>{{Cite web |date=2019 |title=Advancing Gene, Cell, & Tissue-Based Therapies |url=https://alliancerm.org/sector-report/2019-annual-report/ |url-status=live |archive-url=https://web.archive.org/web/20220215045248/https://alliancerm.org/sector-report/2019-annual-report/ |archive-date=2022-02-15 |access-date=2022-06-06 |website=Alliance for Regenerative Medicine |language=en}}</ref> The alliance is an international advocacy organization supporting the development of [[regenerative medicine]]s including [[gene therapy]] and [[stem-cell therapy]].\n* [[Arthritis Australia]] - Donor.<ref>{{Cite web |title=Our Supporters |url=https://arthritisaustralia.com.au/about-us/our-supporters/ |access-date=2022-06-13 |website=Arthritis Australia |language=en-AU}}</ref>\n* BioFIT - Sponsor.<ref>{{Cite web |date=2021-11-29 |title=We are very honoured to count Pfizer among the Sponsors of BioFIT 2021 |url=https://www.biofit-event.com/we-are-very-honoured-to-count-pfizer-among-the-sponsors-of-biofit-2021/ |url-status=live |archive-url=https://web.archive.org/web/20220612193241/https://www.biofit-event.com/we-are-very-honoured-to-count-pfizer-among-the-sponsors-of-biofit-2021/ |archive-date=2022-06-12 |access-date=2022-06-12 |website=BioFIT 2022 |language=en-GB}}</ref> BioFIT holds events to connect academia, pharmaceutical companies, and investors in the field of [[life sciences]] and [[biotechnology]].\n* Canadian Frailty Network - Industry partner.<ref>{{Cite web |title=Industry and Association Partners |url=https://www.cfn-nce.ca/get-involved/our-partners/industry-and-association-partners/ |url-status=live |archive-url=https://archive.today/20220328002018/https://www.cfn-nce.ca/get-involved/our-partners/industry-and-association-partners/ |archive-date=March 28, 2022 |access-date=2022-03-28 |website=Canadian Frailty Network |language=en-US }}</ref> CFN has provided research grants related to [[COVID-19]].<ref>{{Cite web |last=Kim |first=Perry |date=2020-04-07 |title=Request for Proposals (RFP) Frailty and COVID-19 |url=https://www.cfn-nce.ca/wp-content/uploads/2020/04/RFP-Frailty-and-COVID-April-7.pdf |url-status=live |archive-url=https://web.archive.org/web/20220302175728/https://www.cfn-nce.ca/wp-content/uploads/2020/04/RFP-Frailty-and-COVID-April-7.pdf |archive-date=2022-03-02 |access-date=2022-03-27 |website=Canadian Frailty Network}}</ref>\n* Colorectal Cancer Canada - Sponsor.<ref>{{Cite web |date=2021 |title=Our Partnerships |url=https://www.colorectalcancercanada.com/what-we-do/our-partnerships/ |url-status=live |archive-url=https://web.archive.org/web/20220516082302/https://www.colorectalcancercanada.com/what-we-do/our-partnerships/ |archive-date=2022-05-16 |access-date=2022-05-16 |website=Colorectal Cancer Canada |language=en}}</ref><ref>{{Cite web |date=2022-02-28 |title=In Conversation with Barry Stein |url=https://www.pfizer.ca/conversation-barry-stein |url-status=live |archive-url=https://web.archive.org/web/20220516182657/https://www.pfizer.ca/conversation-barry-stein |archive-date=2022-05-16 |access-date=2022-05-16 |website=Pfizer Canada |language=en}}</ref>\n* [[Drugs for Neglected Diseases Initiative]] - Partner.<ref>{{Cite web |date=2020-04-24 |title=Our partners |url=https://dndi.org/partnerships/industry-partners/ |url-status=live |archive-url=https://archive.today/20220603181048/https://dndi.org/partnerships/industry-partners/ |archive-date=June 3, 2022 |access-date=2022-06-06 |website=[[Drugs for Neglected Diseases Initiative]] |language=en-GB }}</ref> DNDI is a non-profit [[drug research and development]] organization that expedites creation and delivery of medicines for diseases including [[leishmaniasis]], [[sleeping sickness]], and [[hepatitis C]].\n* [[GISAID]] - Funding for COVID-19 operations.<ref>{{Cite web |date=2022 |title=Grants and Donations |url=https://www.gisaid.org/about-us/grants-and-donations/ |url-status=live |archive-url=https://web.archive.org/web/20220620035459/https://www.gisaid.org/about-us/grants-and-donations/ |archive-date=2022-06-20 |access-date=2022-07-01 |website=[[GISAID]]}}</ref>\n* [[Heart and Stroke Foundation of Canada]] - National corporate partner and sponsor.<ref>{{Cite web |title=Our partners |url=https://www.heartandstroke.ca/en/what-we-do/partners/ |url-status=live |archive-url=https://archive.today/20220509221919/https://www.heartandstroke.ca/what-we-do/partners |archive-date=May 9, 2022 |access-date=2022-05-16 |website=Heart and Stroke Foundation of Canada |language=en }}</ref><ref>{{Cite web |date=2018-04-27 |title=Pfizer Canada announces support to Heart & Stroke's #TimeToSeeRed campaign |url=https://www.pfizer.ca/pfizer-canada-announces-support-heart-stroke%E2%80%99s-timetoseered-campaign |url-status=live |archive-url=https://web.archive.org/web/20220516183729/https://www.pfizer.ca/pfizer-canada-announces-support-heart-stroke%E2%80%99s-timetoseered-campaign |archive-date=2022-05-16 |access-date=2022-05-16 |website=Pfizer Canada |language=en}}</ref>\n* Lung Health Foundation - Partner.<ref>{{Cite web |title=Our Partners |url=https://lunghealth.ca/our-partners/ |url-status=live |archive-url=https://archive.today/20220609004346/https://lunghealth.ca/our-partners/ |archive-date=June 9, 2022 |access-date=2022-06-09 |website=Lung Health Foundation |language=en-US }}</ref> Funds research into infectious lung disease and lobbying for policy changes.\n* Mentoring in IBD - Sponsor. Annual educational program for Canadian [[Gastroenterology|gastroenterologists]].<ref>{{Cite web |title=Sponsors |url=https://www.mentoringinibd.com/about-us/sponsors/ |url-status=live |archive-url=https://archive.today/20220419151936/https://www.mentoringinibd.com/about-us/sponsors/ |archive-date=April 19, 2022 |access-date=2022-04-19 |website=Mentoring in IBD }}</ref>\n* [[Mount Sinai Hospital (Toronto)]] - Sponsor for research into [[infectious diseases]] such as [[COVID-19]] through educational grants.<ref>{{Cite web |title=COVID-19 Cohort Study (CCS): Study of the epidemiology of COVID-19 in healthcare workers and their households |url=https://www.tibdn.ca/covid-19/sinai |url-status=live |archive-url=https://web.archive.org/web/20220516190343/https://www.tibdn.ca/covid-19/sinai |archive-date=2022-05-16 |access-date=2022-05-16 |website=TIBDN: Toronto Invasive Bacterial Diseases Network |language=en}}</ref>\n* Nova Scotia Chronic Pain Collaborative Care Network - Investment in Canadian health research.<ref>{{Cite web |date=2016-02-12 |title=Response Package HTH-2015-51828 |url=http://docs.openinfo.gov.bc.ca/Response_Package_HTH-2015-51828.pdf |url-status=live |archive-url=https://web.archive.org/web/20220428045844/http://docs.openinfo.gov.bc.ca/Response_Package_HTH-2015-51828.pdf |archive-date=2022-04-28 |access-date=2022-07-01 |website=[[Government of British Columbia]]}}</ref>\n* Ontario Hospital Research Institute (OHRI) - Research grants.<ref>{{Cite web |last=Ganton |first=Jennifer |date=2015-10-22 |title=Drugs commonly used in kidney transplant patients not as effective as previously thought |url=https://www.ohri.ca//newsroom/story/view/622?l=en |url-status=live |archive-url=https://web.archive.org/web/20220513165109/http://www.ohri.ca/newsroom/story/view/622?l=en |archive-date=2022-05-13 |access-date=2022-07-01 |website=Ottawa Hospital Research Institute}}</ref>\n* Pinnacle Research Group - Sponsor.<ref>{{Cite web |title=Sponsors and CRO's |url=http://www.pinnacletrials.com/sponsors/ |url-status=live |archive-url=https://web.archive.org/web/20220612095624/http://www.pinnacletrials.com/sponsors/ |archive-date=2022-06-12 |access-date=2022-06-12 |website=Pinnacle Research Group |language=en-US}}</ref>\n* Radcliffe Cardiology - Industry partner.<ref>{{Cite web |date=2022 |title=A-Z |url=https://www.radcliffecardiology.com/products-services/a-z |url-status=live |archive-url=https://web.archive.org/web/20220612062914/https://www.radcliffecardiology.com/products-services/a-z |archive-date=2022-06-12 |access-date=2022-07-01 |website=Radcliffe Cardiology}}</ref>\n* [[Truth Initiative]] - Featured partner.<ref>{{Cite web |date=2022 |title=Featured partnerships |url=https://truthinitiative.org/what-we-do/partnerships/featured-partnerships |url-status=live |archive-url=https://web.archive.org/web/20220721005439/https://truthinitiative.org/what-we-do/partnerships/featured-partnerships |archive-date=2022-07-21 |access-date=2022-07-21 |website=[[Truth Initiative]] |language=en}}</ref> The initiative performs research and policy studies related to the reduction of tobacco use in youth.\n\n==See also==\n{{Portal|New York City|Companies}}\n* [[Biotech and pharmaceutical companies in the New York metropolitan area]]\n* [[Companies of the United States with untaxed profits]]\n* [[Fire in the Blood (2013 film)|''Fire in the Blood'' (2013 film)]]\n* [[List of pharmaceutical companies]]\n\n==References==\n{{Reflist}}\n\n==External links==\n{{Commons category}}\n*{{official website}}\n{{Finance links\n| name = Pfizer Inc.\n| google = PFE\n| yahoo = PFE\n| bloomberg = PFE:US\n| symbol = PFE\n| sec_cik = PFE\n| nasdaq = PFE\n}}\n* [https://www.usaspending.gov/recipient/515252d5-06e8-c533-c04f-cbeabd17d69f-P Pfizer Inc.] recipient profile on [[USAspending.gov]]\n\n{{Pharmaceutical companies of the United States}}\n{{authority control}}\n\n[[Category:Pfizer| ]]\n[[Category:1849 establishments in New York (state)]]\n[[Category:1940s initial public offerings]]\n[[Category:American brands]]\n[[Category:American companies established in 1849]]\n[[Category:Biotechnology companies of the United States]]\n[[Category:Clinical trial organizations]]\n[[Category:Companies based in Manhattan]]\n[[Category:Companies listed on the New York Stock Exchange]]\n[[Category:Companies listed on the Bombay Stock Exchange]]\n[[Category:Former components of the Dow Jones Industrial Average]]\n[[Category:Life sciences industry]]\n[[Category:Multinational companies based in New York City]]\n[[Category:Orphan drug companies]]\n[[Category:Pharmaceutical companies established in 1849]]\n[[Category:Pharmaceutical companies of the United States]]\n[[Category:Publicly traded companies based in New York City]]\n[[Category:Research and development in the United States]]\n[[Category:Vaccine producers]]\n[[Category:COVID-19 vaccine producers]]"}